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STILBENE ANALOGS AND METHODS OF 
TREATING CANCER 
2 
radation. Although these agents inhibit W nt signaling in nor-
mal cells and some APC-mutated colon cancer cells, they 
may not be effective in colon cancer cells containing ~-cate­
nin mutations. Several other Wnt inhibitors have also been CROSS-REFERENCE TO RELATED 
APPLICATION 
This application is a Divisional ofU.S. application Ser. No. 
13/360,109, filed on Jan. 27,2012, which claims the benefit of 
both U.S. Provisional Application No. 61/437,341 filed Jan. 
28, 2011 and U.S. Provisional Application No. 61/439,118, 
filed Feb. 3, 2011, the entire disclosures of which are incor-
porated by reference herein. 
5 reported. However, side effects limit their potential use in 
hnmans. Natural products found in foods are potentially ideal 
chemopreventive and therapeutic agents for cancer if they 
possess sufficient potency and minimal toxicity. 
Therefore, there is an ongoing need for compounds that are 
10 more potent than resveratrol and pterostilbene and that can be 
used to treat cancer and other ailments. There is also a par-
ticular need for compounds that do not exhibit deleterious 
side effects. 
SEQUENCE LISTING 
15 
The application contains a Sequence Listing which has 
been submitted in ASCII format via EFS-Web and is hereby 
incorporated by reference in its entirety. The Sequence List-
ing was previously submitted in parent application Ser. No. 
13/360,109. Said ASCII copy, created on May 14, 2014, is 20 
named SequenceListing_050229_0626.txt, and it is 5,375 
bytes in size. 
SUMMARY OF THE DISCLOSURE 
Advantages of the present disclosure include halogenated 
stilbene analogs and compositions having antineoplastic 
activity and methods of inhibiting cancer cell growth and/or 
treating cancer in a patient by administering one or more of 
the halogenated stilbene analogs or compositions. 
One aspect of the present disclosure is directed to haloge-
nated stilbene analogs that are useful for killing hyperprolif-STATEMENT REGARDING FEDERALLY 
SPONSORED RESEARCH 
This invention was made with govermnent support under 
2P20 RR020171 awarded by The National Institutes of 
Health. The government has certain rights in the invention. 
25 erating cells such as cancer cells for the treatment of human 
malignant and benign cancers, including without limitation, 
colorectal cancer (CRC), liver and breast cancer. In this 
aspect of the disclosure, there are provided certain haloge-
nated stilbene analogs having anti-neoplastic activity against 
TECHNICAL FIELD 
30 cancerous cells. The halogenated stilbene analogs of the 
present disclosure include compounds according to formula 
(I): 
The present disclosure is directed to compounds having 
antineoplastic activity. In particular, the disclosure is directed 
to halogenated stilbene analogs and methods of identifying 35 
the specific molecular target of the stilbene analogs and inhib-
iting cancer cell growth in a patient by administering the 
stilbene analogs to the patient. Additionally, the present dis-
closure is directed to the direct target of stilbene analogs, 
methionine adenosyltransferase 2A (MAT2A), and methods 40 
of detecting the levels of MAT2A in a complex protein mix-
ture. 
BACKGROUND 
X-Ar1---'=Ra=CRb-Ar2 (I) 
wherein Ra and R6 are independently H, alkyl, halo, alkoxy, 
cyano; X represents at least one halogen, e.g., a fluorine, 
chlorine, bromine, or iodine substituent, on Ar 1 ; each of Ar 1 
and Ar2 are aryl, e.g., phenyl, naphthyl, and heteroaryl, e.g., 
pyridyl, pyrolidyl, piperidyl, pyrimidyl, indolyl, thienyl, 
which can be further substituted with halo, amino, alky-
lamino, dialkylamino, arylalkylamino, N-oxides of dialky-
lamino, trialkylarmnoninm, mercapto, alkylthio, alkanoyl, 
nitro, nitrosyl, cyano, alkoxy, alkenyloxy, aryl, heteroaryl, 
sulfonyl, sulfonamide, CONR11 Rw NR11 CO(R13), 
Resveratrol (trans- or (E)-3,5,4'-trihydroxystilbene (1)) 
(FIG. 1) is a phytoalexin produced in plants and popularized 
as a beneficial ingredient of red wine. Resveratrol, its cis- or 
(Z)-isomer (2), and another stilbene derivative, pterostilbene 
(3), exhibit some anti-cancer activity. (FIG. 1) Recently, we 
found that resveratrol and pterostilbene, a stilbene found in 
blueberries, inhibit colon cancer cells at least partially 
through inhibiting Wnt/~-catenin signaling. Zhang, W. eta!., 
45 NR11 COO(R13), NR11CONR12R13 where R1 u R12, R13 , are 
independently, H, alkyl, aryl, heteroaryl or a fluorine; pro-
vided thatAr2 contains at least one nitrogen atom in the aryl 
ring or at least one nitrogen substituent on the aryl ring; e.g., 
an NRcRdz substituent where Rc is H, alkyl, alkoxy, aryl, 
50 heteroaryl, Rd is an alkyl group, Z is a an unshared pair of 
electrons, H, alkyl, oxygen; or a pharmaceutically acceptable 
salt thereof. 
J Med Chern 2011, 54, 1288-97. 
Wnt/~-catenin signaling plays an important role in devel- 55 
opment and tnmorigenesis, and the deregulation ofWnt sig-
naling results in formation of tumors. Over 90% of colorectal 
cancers contain a mutation in APC or ~-catenin, and these 
mutations stabilize ~-catenin and activate Wnt signaling. 
Cells containing these mutations constitutively activate Wnt 60 
signaling and undergo strong proliferation that ultimately 
leads to cancer. Intercepting and blocking the Wnt/~-catenin 
pathway at various points in the signaling cascade is an attrac-
tive target for colon cancer chemoprevention and therapeu-
tics. 65 
Several Wnt inhibitors have been identified that target the 
upstream signaling of ~-catenin and promote ~-catenin deg-
In another embodiment of the present disclosure, the halo-
genated stilbene analogs include compounds of formula (II): 
(II) 
or a pharmaceutically acceptable salt thereof, wherein each of 
Ra and R6 are as defined above; 
US 9,132,102 B2 
3 
R1 to R10 are independently H, halo, amino, alkylamino, 
dialkylamino, N-oxides of dialkylamino, arylalkylamino, 
dialkyloxyamino, trialkylammonium, mercapto, alkylthio, 
alkanoyl, nitro, nitrosyl, cyano, alkoxy, alkenyloxy, aryl, het-
eroaryl, sulfonyl, sulfonamide, CONR11 Rw NR11 CO(R13), 
NR11 COO(R13), NR11 CONR12R13 where R1 u Rw R13, are 
independently, H, alkyl, aryl, heteroaryl or a fluorine; pro-
vided at least one of R1 to R5 is a halogen, e.g. a fluorine 
and/or chlorine; and at least one of R6 to R10 is a nitrogen 
containing substituent, e.g., an NR'Rdz substituent where Rc 
isH, alkyl, alkoxy, aryl, heteroaryl, Rd is an alkyl group, Z is 
a an unshared pair of electrons, H, alkyl, oxygen. 
In another embodiment of the present disclosure, the halo-
genated stilbene analogs include compounds according to 
formula (III): 
(III) 
4 
and colorectal cancers, which tend to occur more in older 
individuals, e.g., 65 years or older. 
In another aspect of the present disclosure, there is pro-
vided a method for disrupting Wnt signaling and/or other 
pathways using inhibitors of the enzyme, methionine S-ad-
enosyltransferase, in a cell by treating the cell with an effec-
tive amount of a halogenated stilbene analog. These analogs 
can inhibit methionine adenosyltransferase 2A (MAT2A) and 
reduce cellular S-adenosyl-methionine (SAM), which is a 
10 major donor of DNA methylation and protein methylation 
that regulate gene expression and tumor growth. SAM is also 
a key factor in metabolic pathways. Thus, the halogenated 
stilbene analogs described in the present disclosure are also 
drug candidates for treatment of metabolic diseases, such as 
15 diabetes. 
The present disclosure further encompasses a pharmaceu-
tical composition including one or more compounds of for-
mula (I), formula (II) and/or formula (III) and/or one or more 
pharmaceutically acceptable salt, solvate, hydrate, prodrug or 
20 metabolite thereof, for treatment of a disorder associated with 
an increased MAT2A biological activity or levels. In a related 
embodiment, the disorder associated with an increased 
MAT2A biological activity or levels is cancer. In another 
embodiment, the cancer is colon cancer, breast cancer, lung 
25 cancer, prostate cancer or liver cancer. 
or a pharmaceutically acceptable salt thereof, where, R2 , R3 , 
R5 , R6 , R7 , R9 , R10, Ra, R
6 and NRcRdz are the same as 30 
defined above. 
The present disclosure is also directed to a method of 
treating a disorder associated with an increased methionine 
adenosyltransferase 2A (MAT2A) biological activity or lev-
els in a subject including administering to the subject an 
effective amount of one or more compounds of formula (I)-
(III) and/or one or more pharmaceutically acceptable salt, 
The present disclosure also encompasses biotinylated deri-
vates of the halogenated stilbene analogs and metabolites of 
the halogenated stilbene analogs. 
The present disclosure further encompasses pharmaceuti-
cal compositions of the halogenated stilbene analogs, e.g., 
one or more compounds of formula (I), formula (II) and/or 
formula (III) and/or one or more pharmaceutically acceptable 
salts of compounds according to formulas (I), (II) and/or (III), 
in combination with a pharmaceutical carrier. In one aspect of 
the present disclosure, the pharmaceutical compositions 
comprise an effective amount of at least one halogenated 
stilbene analog. 
The present disclosure is further directed to methods of 
treating cancer, e.g., inhibiting cancer cell growth and/or 
inhibiting tumor growth in a mammal, such as a human, or 
treating diseases associated with hyperproliferating cells. In 
one embodiment of this aspect of the disclosure, a therapeu-
tically effective amount of one or more halogenated stilbene 
analogs, pharmaceutical salts and/or compositions thereof is 
administered to a patient in need of treatment of cancer suf-
ficient to treat/inhibit cancer cell growth in the patient. 
solvate, hydrate, prodrug or metabolite thereof. In another 
embodiment, the present disclosure is directed to a method of 
treating a disorder associated with an increased MAT2A bio-
35 logical activity or levels in a subject including administering 
to the subject an effective amount of a composition including 
one or more compounds of formula (I)-(III) and/or one or 
more pharmaceutically acceptable salt, solvate, hydrate, pro-
drug or metabolite thereof. In a related embodiment, the 
40 disorder associated with an increased MAT2A biological 
activity or levels is cancer. In another related embodiment, the 
cancer is colon cancer, breast cancer, lung cancer, prostate 
cancer or liver cancer. 
The present disclosure is also directed to a method of 
45 modulating MAT2A activity in a subject, the method includ-
ing administering to the subject an effective amount of one or 
more compounds offormula (I), formula (II) and/or formula 
(III) and/or one or more pharmaceutically acceptable salt, 
solvate, hydrate, prodrug or metabolite thereof. In a related 
50 embodiment, the modulation of MAT2A activity includes 
decreasing MAT2A biological activity or level in a subject. In 
another related embodiment, the modulation of MAT2A 
activity includes decreasing SAM and/or S-adenosylho-In another embodiment of this aspect of the disclosure, a 
therapeutically effective amount of one or more halogenated 
stilbene analogs, pharmaceutical salts and/or compositions 55 
thereof sufficient to inhibit the cancer cell growth in a patient 
mocysteine (SAH) synthesis. 
The present disclosure is also directed to a method of 
detecting the levels of MAT2A in a complex protein sample, 
said method includes contacting a detectably labeled com-
pound of formula (I)-(III) to said complex protein mixture 
under conditions whereby said labeled compound binds to 
is administered to a patient suffering from colorectal cancer. 
In another embodiment, a therapeutically effective amount of 
one or more halogenated stilbene analogs, pharmaceutical 
salts and/or compositions thereof sufficient to inhibit or treat 
breast cancer. 
In yet another embodiment, a therapeutically effective 
amount of one or more halogenated stilbene analogs, phar-
maceutical salts and/or compositions thereof sufficient to 
inhibit the cancer cell growth in a patient is administered to a 
patient suffering from age-related cancer. Non-limiting 
examples of age-related cancers include prostate, breast, lung 
60 MAT2A present in the sample; isolating the bound MAT2A; 
removing any unbound proteins and detecting the level of the 
MAT2A bound to the detectably labeled compound in the 
sample. In a related embodiment, the isolation of the bound 
MAT2A is carried out by an affinity-based separation 
65 method. In another related embodiment, the compound of 
(I)-(III) is biotinylated. In another related embodiment, the 
detection is conducted by western blot, HPLC, FPLC, ion 
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exchange, size exclusion, fluorescence spectroscopy, UV-Vis 
spectrometry or mass spectrometry. 
The present disclosure is further directed to a method of 
diagnosing cancer in a subject, including: (1) obtaining a 
sample comprising protein from the subject, (2) contacting a 5 
detectably labeled compound of formula (I)-(III) with pro-
teins in the sample to bind to MATA2 and detect the level of 
MAT2A in said sample; and (3) comparing the levels of 
MAT2A in the sample to that of a normal reference, where-
upon if the level of MAT2A in the sample is statistically 10 
higher than that of the normal reference, a diagnosis of cancer 
is indicated. In a related embodiment, the detection in step (2) 
is carried out according to the method described in the pre-
ceeding paragraph. In another related embodiment, the 
15 
sample obtained from a subject is a biopsy sample including 
cancer cells selected from breast, prostate, colorectal, lung, 
colon, bladder, head and neck, intestine, ovarian, or skin 
cancer cells. 
The present disclosure further relates to a method of iden- 20 
tifYing a subject who is a candidate for receiving treatment 
with one or more compounds of formula (I), formula (II) or 
formula (III) or one or more pharmaceutically acceptable salt, 
solvate, hydrate, prodrug or metabolite thereof; said method 
includes (1) obtaining a protein sample from the subject, (2) 25 
contacting a detectably labeled compound of formula (I)-(III) 
with proteins in the sample to bind to MATA2 and detect the 
level ofMAT2A in said sample; and (3) comparing the level 
ofMAT2A in the sample to that in a normal reference, where-
upon if the level of MAT2A in the sample is statistically 30 
higher than that of the normal reference, the candidacy of the 
subject for treatment with compounds of formula (I), formula 
(II) or formula (III) or one or more pharmaceutically accept-
able salt, solvate, hydrate, prodrug or metabolite thereof is 
35 
indicated. In a related embodiment, the detection in step (2) is 
carried out according to the method described in the above 
paragraph describing detecting the levels ofMAT2A in com-
plex protein sample. 
The present disclosure is further directed to kit including 40 
the compounds of the present disclosure. In a related embodi-
ment, the kit includes one or more compounds of formula 
(I)-(III). I another embodiment, the kit includes a composi-
tion including one or more compounds of formula (I)-(III) 
and/or one or more pharmaceutically acceptable salt, solvate, 45 
hydrate, prodrug or metabolite thereof. In a related embodi-
ment, the kit includes one or more other therapeutic com-
pounds or compositions for use in combination therapies. 
In another embodiment, the kit can be a diagnostic kit 
including a detectably labeled compound offormula (I)-(III) 50 
for use as a diagnostic reagent. In another related embodi-
ment, the labeled compound is biotinylated derivative of one 
or more compounds of formula (I), formula (II) and/or for-
mula (III). In another embodiment, the kit includes a binding 
partner of the label of the labeled compound of formula 55 
(I)-(III). 
Additional advantages of the present disclosure will 
become readily apparent to those skilled in this art from the 
following detailed description, wherein only the preferred 
embodiment of the disclosure is shown and described, simply 60 
by way of illustration of the best mode contemplated of car-
rying out the disclosure. As will be realized, the disclosure is 
capable of other and different embodiments, and its several 
details are capable of modifications in various obvious 
respects, all without departing from the disclosure. Accord- 65 
ingly, the drawings and description are to be regarded as 
illustrative in nature, and not as restrictive. 
6 
BRIEF DESCRIPTION OF THE DRAWINGS 
Reference is made to the attached drawings, wherein ele-
ments having the same reference numeral designations rep-
resent similar elements throughout and wherein: 
FIG.l shows the structures of naturally occurring stilbenes 
with antineoplastic activity. Structure 1 is a trans-resveratrol, 
2 is cis-resveratrol and 3 is pterostilbene. 
FIG. 2 is a schematic drawing of the general synthesis of 
certain stilbene analogs and 1 ,2-diarylethanes. Legend: a, (1) 
n-BuLi, THF; (2)ArCHO; b, (1) NaH, DMF; (2)ArCHO; c, 
H2 , Pd---C, THF. 
FIG. 3 shows the chemical structures of several potential 
metabolites of fluorinated and/or chlorinated stilbene analogs 
of the present disclosure. 
FIG. 4 is a schematic drawing of the synthesis of biotin 
derivatives of the halogenated stilbene analogs. Legend: a, 
SnC12 , HCl, HOAc; b, CNBr; c, biotinyl chloride, Et3N, THF; 
d, biotin, HOBt, EDC, Et3N, DMF; e, ( + )-biotinyl-iodoaceta-
midyl-3,6-dioxaoctanediamine, K2 C03 , EtOH. 
FIG. S(A) provides the chemical structures of various 
monofluorinated stilbenes of the present disclosure. FIG. 
S(B) is a Western blot showing 4-aminostilbene ( 4c) represses 
Wnt target genes at 30 f.LM. FIG. S(C) is a Western blot 
showing 4-styryl-N,N-dimethylaniline (4d) is more active 
than 4-methoxystilbene ( 4b) at 30 f.LM. FIG. S(D) is a Western 
blot showing 4-(2-fluorostyryl)-N,N-dimethylaniline ( 4e) 
and 4-(3-fluorostyryl)-N,N-dimethylaniline ( 40 represses 
Wnt target genes at 10 f.LM. FIG. S(E) is a Western blot 
showing the effect of the dimethylaminophenyl group within 
4e. FIG. S(F) is a graph showing the potency of (4e) in 
comparison to that of resveratrol and pterostilbene in inhib-
iting the proliferation ofCRC cells. 
FIG. 6(A) provides the chemical structures of several diha-
logenated N,N-dialkylaminostilbene analogs 4 and a satu-
rated analog 5r of the disclosure. FIG. 6(B) is a Western blot 
showing that dihalogenated N,N -dimethylaminostilbenes 4o, 
4 m and 4 r, repress W nt target genes at 1 0 f.LM. FIG. 6( C) is a 
Western blot showing that the ortho- and meta-isomers of 
N,N -dimethylamino analogs ( 4p and 4q) are not as active as 
the para-isomer ( 4r). FIG. 6(D) is a Western blot showing that 
trihalogenated N,N-dimethylaminostilbene analogs (4v and 
4w) are active Wnt inhibitors. FIG. 6(E) is a Western blot 
demonstrating that compound 4r represses Wnt target genes 
at 0.5 f.LM. 
FIG. 7 demonstrates the effects of halogenated analogs of 
the present disclosure on CRC cell proliferation in vitro and in 
vivo. FIG. 7(A) is a graph showing inhibition of CRC cell 
proliferation at 0.1, 0.3 and 1 f.LM of various compounds of the 
disclosure. FIG. 7(B) shows representative nude mice treated 
with compound 4r or corn oil after injection with LS 17 4 CRC 
cells (2x1 06 ) subcutaneously into both flanks. FIG. 7(C) is a 
graph of the body weights of nude mice treated with com-
pound 4r and corn oil. FIG. 7(D) is a graph of tumor volume 
in mice treated with compound 4r or corn oil. Statistical 
significance was calculated by the student's t test (*p<0.05). 
FIG. S(A) is a bar graph showing fluorescence at 365 nM 
detected by Promega GloMax® Luminometer. FIG. S(B) is a 
Western blot showing compound 4s is an active Wnt inhibitor. 
S(C) is a Western blot showing that compound 4r (10 f.LM) and 
resveratrol (100 f.LM) reduced the protein levels of Wnt/~­
catenin targets in LS174 cells. FIG. S(D) is a Western blot 
showing that compound 4r represses transcription of Wnt 
target genes. 
FIG. 9 relates to affinity purification of stilbene analog 
target. FIG. 9(A) shows a biotinylated derivative 13 of a 
halogenated stilbene analog of the present disclosure. FIG. 
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9(B) shows silver staining of protein markers (1), elutions 
from Biotin-stilbene analog-beads (2), Streptavidin beads 
alone (3) and unrelated biotin-labeled beads ( 4). 
8 
ods for the treatment or prevention of disorders associated 
with MAT2A. Such diseases or disorders include, but not 
limited to, proliferative disorders such as cancer or metabolic 
disorders such as diabetes, heart disease, aging, obesity, and 
neurodegenerative disorders such as Alzheimer and Parkin-
son diseases. 
Definitions 
The term "alkyl" is art-recognized, and includes saturated 
aliphatic groups, including straight-chain alkyl groups, 
FIG. 10 shows halogenated stilbene analogs of the present 
disclosure directly interacted with MAT2A. GST-MAT2A 5 
and GST-MAT2B fusion proteins were expressed and puri-
fied from E. coli. These proteins were incubated with strepta-
vidin beads with or without biotinylated derivative 13. The 
binding proteins were eluted by 2.5 mM D-biotin and ana-
lyzed by Western blot with an anti-GST-Ab. 10 branched-chain alkyl groups, cycloalkyl (alicyclic) groups, 
alkyl substituted cycloalkyl groups, and cycloalkyl substi-
tuted alkyl groups. In certain embodiments, a straight chain or 
branched chain alky I has about 30 or fewer carbon atoms in its 
FIG. 11 shows that halogenated stilbenes are more potent 
than resveratrol in inhibiting the MAT2A activity in produc-
ing SAM and SAH. FIG. llA shows the effects of 10 f.LM of 
compound 4r versus 30 f.LM of resveratrol on SAM levels in 
LS174 colon cancer cells. FIG.llB shows the effects of3 f.LM 15 
of compound4dd and 10 f.LM of compound 4rversus 30 f.LM of 
resveratrol on SAM levels in colon cancer cells. FIG. llC 
shows the effects of 3 f.LM of compound 4dd and 10 f.LM of 
compound 4r versus 30 f.LM of resveratrol on SAH levels in 
colon cancer cells. 20 
backbone (e.g., C1-C30 for straight chain, C3 -C30 for 
branched chain), and alternatively, about 20 or fewer. Like-
wise, cycloalky Is have from about 3 to about 1 0 carbon atoms 
in their ring structure, and alternatively about 5, 6 or 7 carbons 
in the ring structure. The term "alkyl" as used herein also 
includes halosubstituted alkyls. 
The term "aralkyl" is art-recognized and refers to an alkyl 
group substituted with an aryl group (e.g., an aromatic or 
heteroaromatic group). 
FIG. 12 shows that MAT2A and MAT2B are essential for 
cancer cell proliferation and their inhibition at a transcription 
level reduces cancer cell proliferation. Knocking down 
MAT2A gene (12A) and MAT2B gene (12B) with shRNAs 
are shown to inhibit proliferation of liver cancer cell line 
Hep3B (12C). 
FIG. 13 shows a time-course study for the effects of the 
MAT2A and MAT2B genes inhibition on the proliferation of 
colon cancer cells. FIG. 13A shows inhibition of the HT29 
cell proliferation by MAT2A and MAT2B shRNAs. FIG. 13B 
shows inhibition of the LS 17 4 T cell proliferation by MAT2A 
and MAT2B shRNAs. 
FIG. 14 is a chart showing that the halogenated stilbene 
analogs of the present disclosure inhibit proliferation of colon 
cancer cells. 
FIG. 15 is a chart illustrating that the halogenated stilbene 
analogs of the present disclosure inhibit proliferation ofliver 
cancer cells. 
FIG. 16 is a chart showing the effect of the halogenated 
stilbene 4dd toward inhibition of xenograft tumors in nude 
m1ce. 
FIG. 17 shows the inhibitory effects of selected haloge-
nated stilbene analogs on proliferation ofbreast cancer (17 A), 
lung cancer (17B and 17C), carcinoid tumor (17D) and pros-
tate cancer (17E) cell lines. 
FIG. 18A shows a mutant MAT2A (K265L) that was pre-
pared to conduct binding studies for the halogenated stilbene 
analogs. FIG. 18B shows that a terminal deletion ofMAT2A 
(MAT2A-short) does not affect the binding of the haloge-
nated stilbene analogs to MAT2A. FIG. 18C shows that 
mutant MAT2A (MAT2A-K265L) partially loses its ability to 
bind to halogenated stilbene analogs. 
DETAILED DESCRIPTION OF THE 
DISCLOSURE 
The present disclosure relates to novel inhibitors of the 
enzyme methionine adenosyltransferase 2A (MAT2A) (Ge-
neiD: 4144; nucleotide NM_005911; amino acid ID: 
The terms "alkenyl" and "alkynyl" are art-recognized and 
refer to unsaturated aliphatic groups analogous in length and 
25 possible substitution to the alkyls described above, but that 
contain at least one double or triple bond respectively. 
Unless the number of carbons is otherwise specified, 
"lower alkyl" refers to an alkyl group, as defined above, but 
having from one to about ten carbons (C1 -C10), e.g., from one 
30 to about six carbon atoms (C1-C6) in its backbone structure. 
Likewise, "lower alkenyl" "loweralkyl, "lower amino", 
"lower alkynyl", etc. have similar chain lengths. 
The term "unit dose" or "dosage" refers to physically dis-
crete units suitable for use in a subject, each unit containing a 
35 predetermined-quantity of the therapeutic composition cal-
culated to produce the desired responses discussed above in 
association with its administration, i.e., the appropriate route 
and treatment regimen. The quantity to be administered, both 
according to number of treatments and unit dose, depends on 
40 the protection or effect desired. 
The term "treat" and "treatment" refer to both therapeutic 
treatment and prophylactic or preventative measures, wherein 
the object is to prevent or slow down (lessen) an undesired 
pathological change or disorder, such as the development or 
45 spread of cancer. For purpose of this disclosure, beneficial or 
desired clinical results include, but are not limited to, allevia-
tion of symptoms, diminishment of extent of disease, stabi-
lized (i.e., not worsening) state of disease, delay or slowing of 
disease progression, amelioration or palliation of the disease 
50 state, and remission (whether partial or total), whether detect-
able or undetectable. For example, "treatment" can include a 
qualitative or quantitative reduction (e.g., by at least 10%, 
20%,30%,40%,50%,60%,70%,80%,90%,95%, or more) 
in the tumor or metastases size or reduce or prevent metastatic 
55 growth. "Treatment" can also mean prolonging survival as 
compared to expected survival if not receiving treatment. 
NP _005902). These compounds are useful for treating or 60 
preventing any disease and/or condition, wherein modulation 
Those in need of treatment include those already with the 
condition or disorder as well as those prone to have the 
condition or disorder or those in which the condition or dis-
order is to be prevented. 
The phrase "therapeutically effective amount" means an 
amount of a compound of the present disclosure that (i) treats 
or prevents the particular disease, condition, or disorder, (ii) 
attenuates, ameliorates, or eliminates one or more symptoms 
of the particular disease, condition, or disorder, or (iii) pre-
vents or delays the onset of one or more symptoms of the 
of MAT2A levels, and/or its enzymatic products (i.e., S-ad-
enosyl-methionine (SAM or AdoMet)), is effective in ame-
liorating symptoms or diseases Inhibition ofMAT2A can lead 
to decrease in SAM levels and a reduction in the methylation 65 
reactions or methylated products downstream of SAM. Thus, 
the disclosure provides compounds, compositions and meth- particular disease, condition, or disorder described herein. In 
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the case of cancer, the therapeutically effective amount of the 
drug may be reduce the number of cancer cells; reduce the 
tumor size; inhibit (i.e., slow to some extent and preferably 
stop) cancer cell infiltration into peripheral organs; inhibit 
(i.e., slow to some extent and preferably stop) tumor metasta-
sis; inhibit, to some extent, tumor growth; and/or relieve to 
some extent one or more of the symptoms associated with the 
cancer. To the extent the drug may prevent growth and/or kill 
existing cancer cells, it may be cytostatic and/or cytotoxic. 
For cancer therapy, efficacy can be measured, for example, by 
assessing the time to disease progression (TTP) and/or deter-
mining the response rate (RR). 
The terms "cancer" and "cancerous" refer to or describe the 
physiological condition in mammals that is typically charac-
terized by unregulated cell growth. A "tumor" comprises one 
or more cancerous cells. Examples of cancer include, but are 
not limited to, carcinoma, lymphoma, blastoma, sarcoma, 
and leukemia or lymphoid malignancies. More particular 
examples of such cancers include squamous cell cancer (e.g., 
epithelial squamous cell cancer), lung cancer including 
small-cell lung cancer, non-small cell lung cancer 
("NSCLC"), adenocarcinoma of the lung and squamous car-
cinoma of the lung, cancer of the peritoneum, hepatocellular 
cancer, gastric or stomach cancer including gastrointestinal 
cancer, pancreatic cancer, glioblastoma, cervical cancer, ova-
rian cancer, liver cancer, bladder cancer, hepatome, breast 
cancer, colon cancer, rectal cancer, colorectal cancer, 
endometrial or uterine carcinoma, salivary gland carcinoma, 
kidney or renal cancer, prostate cancer, vulval cancer, thyroid 
cancer, hepatic carcinoma, anal carcinoma, penile carcinoma, 
as well as head and neck cancer. 
The term "prodrug" as used in this application refers to a 
precursor or derivative form of a compound of the disclosure 
that may be less cytotoxic to cells compared to the parent 
compound or drug and is capable of being enzymatically or 
hydrolytically activated or converted into the more active 
parent form. The prodrugs of this disclosure include, but are 
not limited to, phosphate-containing prodrugs, thiophos-
phate-containing prodrugs, sulfate-containing prodrugs, pep-
tide-containing prodrugs, D-amino acid-modified prodrugs, 
glycosylated prodrugs, ~-lactam-containing prodrugs, 
optionally substituted phenoxyacetamide-containing pro-
drugs, optionally substituted phenylacetamide-containing 
prodrugs, 5-fluorocytosine and other 5-fluorouridine pro-
drugs which can be converted into the more active cytotoxic 
free drug. 
A "metabolite" is a product produced through metabolism 
10 
of particular tissues from one or more healthy subjects, or a 
pooled sample of tissues from one or more healthy subjects. 
The phrase "biological activity of MAT2A" or "MAT2A 
biological activity" as used herein, refers to all inherent bio-
logical properties of methionine adenosyltransferase 2A 
(MAT2A) enzyme. Biological properties ofMAT2A include 
but are not limited to catalyzing the transfer of the adenosyl 
group of ATP to the sulfur atom of methionine and producing 
S-adenosyl-methionine (SAM or AdoMet); involving in an 
10 abnormal cell growth and proliferation in cancer cells; facili-
tating intracellular methylation reactions through the action 
of SAM as a methyl group donor. 
The term "labeled" or "detectably labeled" as used herein 
means joining, either covalently or non-covalently to the 
15 compounds of the present disclosure, a substance which elic-
its a physical or chemical response that can be observed or 
detected by a binding partner such as biotin/streptavidin, 
antigen/antibody or by means of instrumentation such as, 
without limitation, UVNis spectrophotometers, flow cytom-
20 eters, fluorescence detection instruments and the like, by the 
naked eye. A wide variety of labels and labeling techniques 
are well known in the art. Suitable labels include biotin, 
radionuclides, e.g., 32P, 35S, 3H, enzymes, substrates, cofac-
tors, inhibitors, fluorescent moieties, chemiluminescent moi-
25 eties, magnetic particles, and the like. 
The phrase "binds to" when referring to the binding of the 
labeled compounds of the present disclosure to MAT2A for 
detection purposes, refers to a binding reaction which is 
determinative of the presence of the MAT2A in the presence 
30 of a heterogeneous population of proteins and other biologics. 
Thus, under binding assay conditions, for example, a labeled 
compound of the present disclosure binds to MAT2A and 
does not bind in a significant amount to other proteins present 
in the sample. A variety of conventional detection means can 
35 be used for detecting the binding of the labeled compounds to 
MAT2A, such as western blot, flow cytometry and FACS 
analysis, immunohistochemistry and the like. See, e.g., Har-
low and Lane Anti bodies, A Laboratory Manual., Cold Spring 
Harbor Publications, NY (1988) for a description of, e.g., 
40 western blot or immunofluorescence assay. Typically, a spe-
cific or selective binding reaction will be at least twice the 
background signal or noise and more typically more than 10 
to 1 00 times background. 
Accordingly, the disclosure includes metabolites of com-
45 pounds of the disclosure, including compounds produced by 
a process comprising contacting a compound of this disclo-
sure with a mammal for a period of time sufficient to yield a 
metabolic product thereof. in the body of a specified compound or salt thereof. Metabo-
lites of a compound may be identified using routine tech-
niques known in the art and their activities determined using 50 
tests such as those described herein. Such products may result 
for example from the oxidation, reduction, hydrolysis, ami-
dation, deamidation, esterification, deesterification, enzy-
matic cleavage, and the like, of the administered compound. 
Therapeutic Agents 
Disclosed herein are halogenated stilbene analogs and their 
use in mitigating hyperproliferating cells or treating diseases 
or disorders associated with MAT2A activity. The haloge-
nated stilbene analogs of the present disclosure display anti-
tumor activity, i.e., cancer cells that are exposed to the com-
The term "complex protein sample" is used to distinguish 
a sample from a purified protein sample. A complex protein 
sample contains multiple proteins, and may additionally con-
tain other contaminants. Non-limiting examples of a complex 
protein samples include tumor tissues, biopsy samples, serum 
or cell extracts. 
By "reference sample" is meant any sample, standard, or 
level that is used for comparison purposes. A "normal refer-
ence sample" can be a prior sample taken from the same 
subject, a sample from a subject not having cancer, a subject 
that is diagnosed with cancer but not a metastatic disease, a 
subject that has been treated for either cancer, metastatic 
disease, or both, a subject that has a benign tumor, or a sample 
55 pounds are killed, damaged and/or tumor growth is inhibited. 
60 
The analogs are useful for treatment of human cancers includ-
ing colorectal cancer, liver, breast cancer, among others. 
The halogenated stilbene analogs of the present disclosure 
include compounds according to formula (I): 
X-Ar1---'=Ra=CRb-Ar2 (I) 
where Ra and R6 are independently H, alkyl, halo, alkoxy, 
cyano; X represents at least one halogen, e.g., a fluorine, 
chlorine, bromine, or iodine substituent, on Ar 1 ; each of Ar 1 
65 and Ar2 are aryl, e.g., phenyl, naphthyl, and heteroaryl, e.g., 
pyridyl, pyrolidyl, piperidyl, pyrimidyl, indolyl, thienyl, 
which can be further substituted with halo, amino, alky-
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!amino, dialkylamino, arylalkylamino, N-oxides of dialky-
lamino, trialkylammonium, mercapto, alkylthio, alkanoyl, 
nitro, nitrosyl, cyano, alkoxy, alkenyloxy, aryl, heteroaryl, 
sulfonyl, sulfonamide, CONR11 Rw NR11 CO(R13), 
NR11 COO(R13), NR11 CONR12R13 where R1 v Rw R13, are 5 
independently, H, alkyl, aryl, heteroaryl or a fluorine; pro-
vided that Ar2 contains at least one nitrogen atom in the aryl 
ring or at least one nitrogen substituent on the aryl ring; e.g., 
an NR"Rdz substituent onAr2 where Rc isH, alkyl, alkoxy, 
aryl, heteroaryl, Rd is an alkyl group, Z is a an unshared pair 10 
of electrons, H, alkyl, oxygen. Preferably, the heteroaryl 
group is a monocyclic ring, wherein the ring comprises 2 to 5 
carbon atoms and 1 to 3 heteroatoms, referred to herein as 
"(C2 -C5 ) heteroaryl". This embodiment also includes a phar- 15 
maceutically acceptable salt offormula (I) and a biotinylated 
derivative of formula (I). The substituents on the carbon-
carbon double bond can be in either the cis- or trans-configu-
ration. In one aspect of the present disclosure, X is one, two or 
three fluorine substituents and/or X is one, two or three chlo- 20 
rine substituents and/or X represents at least one fluorine and 
at least one chlorine on Ar 1 . In another aspect of the present 
disclosure, X is one or more fluorine and/or chlorine and Rc is 
H or a lower alkyl and Rd is a lower alkyl, or a pharmaceuti-
cally acceptable salt thereof, or a biotinylated derivative 25 
thereof. 
In another embodiment, the present disclosure includes 
compounds of formula (II): 
12 
(III) 
whereRv R2 , R3 , R5 , R6 , R7 , R9 , RIO, Ra, R
6 andNRcRdZare 
the same as defined above, or pharmaceutically acceptable 
salts thereof, or a biotinylated derivative thereof. In one 
aspect of the present disclosure, Ra, R6 are both H, one or 
more ofRv R2 , R3 , or R5 , are fluorine or chlorine and Rc isH 
or lower alkyl, such as a methyl, ethyl, propyl group, and Rd 
is a lower alkyl, such as a methyl, ethyl, propyl group. In 
another aspect of the present disclosure, Ra, R6 are both H, 
and at least two of R1 , R2 , R3 , or R5 are fluorine and/or 
chlorine, or a pharmaceutically acceptable salt thereof, or a 
biotinylated derivative thereof. 
In another embodiment of the present disclosure, the halo-
genated stilbene analog is a dihalogenated N,N -dimethylami-
nostyrene having at least one fluorine or chlorine is in the 2' or 
3' position of the aryl ring. In another embodiment, the stil-
bene analog has a fluorine in the 2' position and another 
fluorine in the 6' position. In another embodiment, the stil-
(II) 
30 bene analog has a fluorine in the 2' position and a chlorine in 
the 6' position. In another embodiment, the stilbene analog 
has a chlorine in the 2' position and another chlorine in the 6' 
position. 
where Ra and R6 are as defined above, R1 to RIO are indepen-
dently H, halo, amino, alkylamino, dialkylamino, N -oxides of 
dialkylamino, arylalkylamino, dialkyloxyamino, trialkylam-
monium, mercapto, alkylthio, alkanoyl, nitro, nitrosyl, cyano, 
alkoxy, alkenyloxy, aryl, heteroaryl, sulfonyl, sulfonamide, 
CONR11 R12, NR11 CO(R13), NR11 COO(R13), 
NR11 CONR12R13 where R1 v R12, R13 , are independently, H, 
alkyl, aryl, heteroaryl or a fluorine; provided at least one ofR1 
to R5 is a halogen, e.g. a fluorine and/or chlorine; and at least 
one ofR6 to RIO is a nitrogen containing substituent, e.g., an 
NRcRdz substituent where Rc isH, alkyl, e.g., a lower alkyl, 
alkoxy, aryl, heteroaryl, Rd is an alkyl group, Z is a an 
unshared pair of electrons, H, alkyl, oxygen, or a pharmaceu-
tically acceptable salt thereof, or a biotinylated derivative 
thereof. 
In other embodiments of the present disclosure, at least one 
of R1 to R5 is a chlorine and/or fluorine substituent; at least 
one ofR6 to RIO is NRcRdz where Rc isH or lower alkyl and 
R dis a lower alkyl. In certain embodiments, one, two or three 
ofR1 to R5 is a fluorine or a chlorine group; while in certain 
embodiments R1 and R5 are each fluorine and/or chlorine 
groups, e.g., R1 and R5 are either two fluorine, two chlorine or 
one each of fluorine and chlorine groups. In another embodi-
ment R1 and R4 are each fluorine and/or chlorine groups, e.g. 
R1 and R4 are either two fluorine, two chlorine or one each of 
fluorine and chlorine groups. 
In another embodiments, the present disclosure includes 
compounds according to formula (III): 
35 
In another embodiment, the stilbene analog is a dihaloge-
nated N-methylaminostyrene in with at least one fluorine or 
chlorine is in the 2' or 3' position. 
Particular halogenated stilbene analogs of the present dis-
closure include (E)-4-(2-Fluorostyryl)-N,N-dimethylaniline; 
40 (E)-4-(3-Fluorostyryl)-N,N -dimethylaniline; (E)-4-( 4-Fluo-
rostyryl)-N,N-dimethylaniline; (E)-4-(2-Fluorostyryl)-N,N-
diethylaniline; (E)-4-(2-Fluorostyryl)-N,N-diphenyl aniline; 
(E)-1-( 4-(2-Fluorostyryl)phenyl)-4-methylpiperazine; (E)-
4-(2-Fluorostyryl)-N,N -dimethylnaphthalen-1-amine; (E)-
45 2-( 4-(2-Fluorostyryl)phenyl)-1-methyl-1H-imidazole; (E)-
4-(2,3-Difluorostyryl )-N,N -dimethy !aniline; (E)-4-(2,4-
Difluorostyryl)-N,N-dimethylaniline; (E)-4-(2,5-
Difluorostyryl)-N,N-dimethylaniline; (E)-2-(2,6-
Difluorostyryl)-N,N-dimethylaniline; (E)-3-(2,6-
50 Difluorostyryl)-N,N-dimethylaniline; (E)-4-(2,6-
Difluorostyry 1)-N,N -dimethylaniline; (E)-4-(2,6-
Difluorostyryl)-N,N-diethylaniline; (E)-4-(3,4-
Difluorostyryl)-N,N-dimethylaniline; (E)-4-(3,5-
55 Difluorostyryl)-N,N -dimethylaniline; (E)-N,N -Dimethyl-4-
(2,3,6-trifluorostyryl)aniline; (E)-N,N-Dimethyl-4-(2,4,6-
trifluorostyryl )aniline; (E)-4-(2-chloro-6-fluorostyry I)-N,N-
dimethylaniline; (E)-4-(2,6-dichlorostyryl)-N,N-
dimethylaniline; (E)-4-(2,6-Difluorophenethyl)-N,N-
60 dimethylaniline; and (E)-2-benzamide-4-(2,6-
difluorostyryl )-N,N -dimethy !aniline. 
Synthesis 
The compounds of the present disclosure, including com-
pounds of Formula (I) to Formula (III), may be prepared by 
65 methods disclosed herein or any other method known in the 
art. One of ordinary skill in the art will know how to modifY 
procedures to obtain the analogs of the present disclosure. In 
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addition, compounds may be prepared using the methods 
described below and in Examples 1 through 3 or modified 
versions thereof. 
FIG. 2 is a schematic of the general synthesis of certain 
halogenated stilbene analogs of the present disclosure. Addi-
tiona! halogenated stilbene analogs of the present disclosure 
can be made by similar methods or known synthetic proce-
dures known in the art in light of the present disclosure. For 
example, as shown in FIG. 2 either Wittig or Wadsworth-
Emmons reactions using phosphonium salts or diethyl phos-
phonates, respectively, with aldehydes provided the (E)-stil-
benes (4) in good yield. The phosphonium salts were 
prepared from the corresponding benzyl bromides and triph-
enylphosphine, and the diethyl phosphonates were prepared 
from the corresponding benzyl bromides and triethyl phos-
phite using the Arbuzov reaction according to standard litera-
ture procedures. Compounds were characterized fully and 
purity (>95%) established through combustion analyses. 
The terms ortho, meta and para are art-recognized term and 
refer to 1,2-, 1,3- and 1,4-disubstituted benzenes, respec-
tively. For example, the names 1,2-dimethylbenzene and 
ortho-dimethylbenzene are synonymous. 
The present disclosure also encompasses potential metabo-
lites of the halogenated stilbene analogs. These include stil-
bene analogs, e.g., general formulae (I), (II) or (III), having a 
dialkyamino substituent which has undergone an oxidation to 
anN -oxide. In one embodiment, the compound is theN -oxide 
of the dihalogenated N,N-dimethylaminostyrene having at 
least one fluorine or chlorine is in the 2' or 3' position. These 
potential metabolites also include halogenated stilbene ana-
logs having a N,N-dialkylamino group which has undergone 
a methylation or a demethylation. In one embodiment, the 
stilbene analog is a dihalogenated N,N,N-trimethylammoni-
umstyrene halide having at least one fluorine or chlorine is in 
the 2' or 6' position. In one embodiment, the analog is a 
dihalogenated N-methylaminostyrene having at least one 
fluorine or chlorine is in the 2' or 3' position. In one embodi-
ment, the analog is a dihalogenated N,N-methylhydroxyami-
nostyrene having at least one fluorine or chlorine in the 2' or 
3' position. 
14 
Accordingly, the disclosure includes metabolites of com-
pounds of formulas (I) to (III), including compounds pro-
duced by a process comprising contacting a compound of this 
disclosure with a mammal for a period of time sufficient to 
yield a metabolic product thereof. 
Metabolite products typically are identified by preparing a 
detectably labeled, for example a radio labeled (e.g., C or H 
isotope) compound of the disclosure, administering it 
parenterally in a detectable dose (e.g., greater than about 0.5 
10 mg/kg) to an animal such as rat, mouse, guinea pig, monkey, 
or to man, allowing sufficient time for metabolism to occur 
(typically about 30 seconds to 30 hours) and isolating its 
conversion products from the urine, blood or other biological 
samples. These products are easily isolated since they are 
15 detectably labeled (others are isolated by the use of antibodies 
capable of binding epitopes surviving in the metabolite). The 
metabolite structures are determined in conventional fashion, 
e.g., by MS, LC/MS or NMR analysis. In general, analysis of 
metabolites is done in the same way as conventional drug 
20 metabolism studies, which are well known to those skilled in 
the art. The metabolite products, so long as they are not 
otherwise found in vivo, are useful in diagnostic assays for 
therapeutic dosing of the compounds of the disclosure. 
Examples oflikely metabolites of compounds offormulas (I) 
25 to (III) are shown in FIG. 3 and synthesized according to 
Example 2. 
Prodrugs of the Compounds of the Disclosure 
In addition to compounds of the disclosure, the disclosure 
also includes pharmaceutically acceptable prodrugs of such 
30 compounds. Prodrugs include compounds wherein an amino 
acid residue, or a polypeptide chain of two or more (e.g., two, 
three or four) amino acid residues, is covalently joined 
through an amide or ester bond to a free amino, hydroxy or 
carboxylic acid group of a compound of the present disclo-
35 sure. The amino acid residues include but are not limited to 
the 20 naturally occurring amino acids commonly designated 
by three letter symbols and also includes phosphoserine, 
phosphothreonine, phosphotyrosine, 4-hydroxyproline, 
hydroxyzine, demosine, isodemosine, gamma-carboxy-
40 glutamate, hippuric acid, octahydroindole-2-carboxylic acid, 
statine, 1 ,2,3,4-tetrahydroisoquinoline-3-carboxylic acid, 
penicillamine, ornithine, 3-methylhistidine, norvaline, beta-
alanine, gma-aminobutyric acid, citrulline, homocysteine, 
The present disclosure also encompasses biotinylated 
derivatives of the halogenated stilbene analogs. Such bioti-
nylated derivatives are useful in identifYing the molecular 
target for these agents. Stilbene analogs encompassed by 
formulas (I), (II) and (III) were synthesized and converted to 45 
biotinylated derivatives. The biotinylated derivatives that 
retain biological activity were used to identify a molecular 
enzyme target for these compounds, methionine S-adenosyl-
transferase. 
homo serine, methy !-alanine, para -benzoy !phenylalanine, 
phenylglycine, propargylglycine, sarcosine, methionine sul-
fone and tert-butylglycine. 
Additional types of prodrugs are also encompassed. For 
instance, a free carboxyl group of a compound of the disclo-
sure can be derivatized as an amide or alkyl ester. As another 
example, compounds of this disclosure comprising free 
hydroxy groups may be derivatized as prodrugs by converting 
In certain embodiments of the present disclosure, the halo- 50 
genated stilbene analogs of the disclosure, or a pharmaceuti-
cally acceptable salt, solvate, hydrate or prodrug thereof, 
inhibit the growth of hyperproliferative cells. In certain 
embodiments of the present disclosure, the halogenated stil-
bene analogs of the disclosure, or a pharmaceutically accept- 55 
able salt, solvate, hydrate or pro drug thereof, inhibit methion-
ine adenosyltransferase 2A (MAT2A) activity and are useful 
the hydroxy group into a group such as, but not limited to, a 
phosphate ester, hemisuccinate, dimethylaminoacetate, or 
phosphoryloxymethyloxycarbonyl group, as outlined in 
Advanced Drug Delivery Reviews, (1996) 19:1-15. Carbam-
ate prodrugs of hydroxy and amino groups are also included, 
as are carbonate prodrugs, sulfonate esters and sulfate esters 
ofhydroxy groups. Derivatization ofhydroxy groups as (acy-
loxy)methyl and (acyloxy)ethyl ethers, wherein the acyl 
in treating diseases or conditions associated with MAT2A, 
e.g., diseases and conditions whose maintenance and/or 
spread require MAT2A. 
Metabolites of Compounds of the Disclosure 
60 group may be an alkyl ester optionally substituted with 
groups including, but not limited to, ether, amine and car-
boxylic acid functionalities, or where the acyl group is an 
amino acid ester as described above, are also encompassed. 
Also falling within the scope of this disclosure are the in 
vivo metabolic products of formulas (I) to (III) described 
herein. Such products may result for example from the oxi-
dation, reduction, hydrolysis, amidation, deamidation, esteri- 65 
fication, deesterification, enzymatic cleavage, and the like, of 
the administered compound. 
Pro drugs of this type are described in J. Med. Chern., (1996), 
39:10. More specific examples include replacement of the 
hydrogen atom with a group such as (C1-C6)alkanoyloxym-
ethyl, 1-((C1-C6)alkanoyloxy)ethyl, 1-methyl-1-((C1-C6) 
US 9,132,102 B2 
15 
alkanoy loxy )ethyl, ( C 1-C6)alkoxycarbony loxymethy I, 
N-( C 1-C6)alkoxycarbony laminomethy I, succinoy I, ( C 1-
C6)alkanoyl, a-amino(C1-C4)alkanoyl, arylacyl and a-ami-
noacyl, or a-aminoacyl-a-aminoacyl, where each a-aminoa-
cyl group is independently selected from the naturally 
occurring L-amina acids, P(O)(OH)2 , -P(O)(O(C1-C6) 
alkyl)2 or glycosyl (the radical resulting from the removal of 
a hydroxyl group of the hemiacetal form of a carbohydrate). 
16 
integrating agents and the like may be used. If desired, the 
tablets or capsules may be enteric-coated or sustained release 
by standard techniques. 
In one embodiment, the compositions are prepared with 
carriers that will protect the active compound(s) against rapid 
elimination from the body, such as a controlled release for-
mulation, including implants and microencapsulated delivery 
systems. Biodegradable, biocompatible polymers can be 
used, such as ethylene vinyl acetate, polyanhydrides, polyg-For additional examples of prodrug derivatives, see, for 
example, a) Design of Prodrugs, edited by H. Bundgaard, 
(Elsevier, 1985) and Methods in Enzymology, Vol. 42, p. 
309-396, edited by K. Widder, eta!. (Academic Press, 1985); 
10 lycolic acid, collagen, polyorthoesters, and polylactic acid. 
Methods for preparation of such formulations will be appar-
ent to those skilled in the art. 
The pharmaceutically acceptable carrier may take a wide 
variety of forms, depending on the route desired for admin-
istration, for example, oral or parenteral (including intrave-
nous). Carriers such as starches, sugars, microcrystalline cel-
lulose, diluents, granulating agents, lubricants, binders and 
disintegrating agents may be used in the case of oral solid 
preparations such as powders, capsules and caplets, with the 
b) A Textbook of Drug Design and Development, edited by 
Krogsgaard-Larsen and H. Bundgaard, Chapter "Design and 
Application of Prodrugs," by H. Bundgaard p. 113-191 15 
(1991); c) H. Bundgaard, Advanced Drug Delivery Reviews, 
8:1-38 (1992); d) H. Bundgaard, eta!., Journal of Pharma-
ceutical Sciences, 77:285 (1988); and e) N. Kakeya, eta!., 
Chern. Pharm. Bull., 32:692 (1984), each of which is specifi-
cally incorporated herein by reference. 20 solid oral preparation being preferred over the liquid prepa-
rations. Preferred solid oral preparations are tablets or cap-
sules, because of their ease of administration. If desired, 
tablets may be coated by standard aqueous or nonaqueous 
Pharmaceutical Compositions 
The present disclosure also encompasses pharmaceutical 
compositions comprising at least one halogenated stilbene 
analog, e.g., one or more compounds of formula (I), formula 
(II) and/or formula (III) and/or one or more pharmaceutically 25 
acceptable salts of compounds according to formulae (I), (II) 
and/or (III), in combination with a pharmaceutical carrier. In 
one aspect of the present disclosure, the pharmaceutical com-
positions comprise an effective amount of at least one halo-
genated stilbene analog. In another embodiment of the 30 
present disclosure, the pharmaceutical composition com-
prises a dihalogenated N,N-dialkylaminostilbene analog and 
a pharmaceutically acceptable carrier. 
While it may be possible for compounds of the present 
disclosure to be administered as the raw chemical, it is pref- 35 
erable to present them as a pharmaceutical composition. 
According to a further aspect, the present disclosure provides 
a pharmaceutical composition comprising a compound or 
mixture of compounds of Formula (I) to Formula (III) or a 
pharmaceutically acceptable salt, solvate, hydrate, prodrug or 40 
metabolite thereof, together with one or more pharmaceutical 
carrier, excipient or additive and optionally one or more other 
therapeutic ingredients. The carrier(s) must be "acceptable" 
in the sense of being compatible with the other ingredients of 
the formulation and not deleterious to the recipient thereof. 45 
The term "pharmaceutically acceptable carrier" includes 
vehicles and diluents. 
techniques. Oral and parenteral sustained release dosage 
forms may also be used. 
Liposomal suspensions may also be pharmaceutically 
acceptable carriers. These may be prepared according to 
methods known to those skilled in the art. For example, lipo-
somal formulations may be prepared by dissolving appropri-
ate lipid(s) in an inorganic solvent that is then evaporated, 
leaving behind a thin film of dried lipid on the surface of the 
container. An aqueous solution of the active compound is then 
introduced into the container. The container is then swirled by 
hand to free lipid material from the sides of the container and 
to disperse lipid aggregates, thereby forming the liposomal 
suspension. Other methods of preparation well known by 
those of ordinary skill may also be used in this aspect of the 
present disclosure. 
In an embodiment, the composition of the present disclo-
sure enables sustained, continuous delivery of a compound of 
Formula (I) to Formula (III) or a pharmaceutically acceptable 
salt, solvate, hydrate, prodrug or metabolite thereof, to tissues 
adjacent to or distant from an administration site. The bio-
logically-active agent is capable of providing a local or sys-
temic biological, physiological or therapeutic effect. For 
example, a compound of Formula (I) to Formula (III) or a 
pharmaceutically acceptable salt, solvate, hydrate, prodrug or 
metabolite thereof, may act to kill cancer cells, or cancer stem 
cells or to control or suppress tumor growth or metastasis, 
To prepare the pharmaceutical compositions, a therapeuti-
cally effective amount of one or more of the halogenated 
stilbene analogs according to the present disclosure may be 
intimately admixed with a pharmaceutically acceptable car-
rier according to conventional pharmaceutical compounding 
techniques to produce a dose. A carrier may take a wide 
variety of forms depending on the form of preparation desired 
for administration, e.g., oral, topical or parenteral, including 
gels, creams ointments, lotions and time released implantable 
preparations, among numerous others. In preparing pharma-
ceutical compositions in oral dosage form, any of the usual 
pharmaceutical media may be used. Thus, for liquid oral 
preparations such as suspensions, elixirs and solutions, suit-
able carriers and additives including water, glycols, oils, alco-
hols, flavoring agents, preservatives, coloring agents and the 
like may be used. For solid oral preparations such as powders, 
tablets, capsules, and for solid preparations such as supposi-
tories, suitable carriers and additives including starches, 
sugar carriers, such as dextrose, mannitol, lactose and related 
carriers, diluents, granulating agents, lubricants, binders, dis-
50 among other functions. 
Formulations and Dosages for Administration 
Pharmaceutical formulations based upon halogenated stil-
bene compounds of the present disclosure comprise at least 
one of the compounds of Formula (I) to Formula (III) or a 
55 pharmaceutically acceptable salt, solvate, hydrate, prodrug or 
metabolite thereof, in a therapeutically effective amount for 
treating neoplasia, cancer and other diseases and conditions 
associated with MAT2A activity such as diabetes, heart dis-
ease, aging, obesity, Alzheimer's disease or Parkinson dis-
60 ease, optionally in combination with a pharmaceutically 
acceptable additive, carrier and/or excipient. One of ordinary 
skill in the art will recognize that a therapeutically effective 
amount of one of more compounds according to the present 
disclosure will vary with the condition to be treated, its sever-
65 ity, the treatment regimen to be employed, the pharmacoki-
netics of the agent used, as well as the patient (animal or 
human) treated. 
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The formulations of the present disclosure include those 
suitable for oral, parenteral (including subcutaneous, intrad-
ermal, intramuscular, intravenous, intratumoral and intraar-
ticular), rectal and topical (including dermal, buccal, sublin-
gual and intraocular) administration, as well as those for 
administration by inhalation. The most suitable route may 
depend upon the condition and disorder of the recipient. 
Exemplary formulations are well known to those skilled in 
the art, and general methods for preparing them are found in 
any standard pharmacy school textbook, for example, Rem-
ington: THE SCIENCE AND PRACTICE OF PHARMACY, 
21st Ed., Lippincott. The formulations of the present disclo-
sure may conveniently be presented in unit dosage form and 
may be prepared by any of the methods well known in the art 
of pharmacy. All methods include the step of bringing into 
association a compound or a pharmaceutically acceptable salt 
or solvate thereof ("active ingredient") with the carrier which 
constitutes one or more accessory ingredients. In general, the 
formulations are prepared by uniformly and intimately bring-
ing into association the active ingredient with liquid carriers 
or finely divided solid carriers or both and then, if necessary, 
shaping the product into the desired formulation. Oral formu-
lations are well known to those skilled in the art, and general 
methods for preparing them are found in any standard phar-
macy school textbook, for example, Remington: THE SCI-
ENCE AND PRACTICE OF PHARMACY, 21st Ed., the 
entire disclosure of which is incorporated herein by reference. 
The concentration of active compound of the present dis-
closure, i.e., at least one of the compounds of Formula (I) to 
Formula (III) or a pharmaceutically acceptable salt, solvate, 
hydrate, prodrug or metabolite thereof, in the drug composi-
tion will depend on absorption, distribution, inactivation, and 
excretion rates of the drug as well as other factors known to 
those of skill in the art. It is to be noted that dosage values will 
also vary with the severity of the condition to be alleviated. 
The composition may be administered at once, or may be 
divided into a number of smaller doses to be administered at 
varying intervals of time. 
Oral compositions will generally include an inert diluent or 
an edible carrier. They may be enclosed in gelatin-capsules or 
compressed into tablets. For the purpose of oral therapeutic 
administration, the active compound or its prodrug derivative 
can be incorporated with excipients and used in the form of 
tablets, troches, or capsules. Pharmaceutically compatible 
binding agents, and/or adjuvant materials can be included as 
part of the composition. 
The tablets, pills, capsules, troches and the like can contain 
any of the following non-limiting ingredients, or compounds 
of a similar nature: a binder such as microcrystalline cellu-
lose, gum tragacanth or gelatin; an excipient such as starch or 
lactose, a dispersing agent such as alginic acid or corn starch; 
a lubricant such as magnesium stearate; a glidant such as 
colloidal silicon dioxide; a sweetening agent such as sucrose 
or saccharin; or a flavoring agent such as peppermint, methyl 
salicylate, or fruit flavoring. When the dosage unit form is a 
capsule, it can contain, in addition to any of the above, a liquid 
carrier such as a fatty oil. In addition, dosage unit forms can 
contain various other materials which modifY the physical 
form of the dosage unit, for example, coatings of sugar, shel-
lac, or enteric agents. 
The tablets, for example, may optionally be coated or 
scored and may be formulated so as to provide sustained, 
delayed or controlled release of the active ingredient therein. 
Oral and parenteral sustained release drug delivery systems 
are well known to those skilled in the art, and general methods 
of achieving sustained release of orally or parenterally admin-
18 
istered drugs are found, for example, in Remington: THE 
SCIENCE AND PRACTICE OF PHARMACY, 21st Ed. 
The active compound may also be administered as a com-
ponent of an elixir, suspension, syrup, wafer or the like. A 
syrup may contain, in addition to the active compounds, 
sucrose or fructose as a sweetening agent and certain preser-
vatives, dyes and colorings and flavors. 
In certain embodiments of the present disclosure, the halo-
genated stilbene analog is formulated as admixture with a 
10 pharmaceutically acceptable carrier, excipient or additive. In 
general, the pharmaceutical composition is administered in 
orally-administrable form, but for treatment of a number of 
conditions, a number of other formulations may be adminis-
tered via a topical, parenteral, intravenous, intramuscular, 
15 transdermal, buccal, subcutaneous, suppository or other 
route, including an eye or ocular route. Intravenous and intra-
muscular formulations are generally administered in sterile 
saline. Of course, one of ordinary skill in the art may modify 
the formulations within the teachings of the specification to 
20 provide numerous formulations for a particular route of 
administration without rendering the pharmaceutical compo-
sitions unstable or compromising their therapeutic activity. It 
is also well within the mutineer's skill to modifY the route of 
administration and dosage regimen of a particular compound 
25 in order to manage the pharmacokinetics of the present com-
pounds for maximum beneficial effect to the patient. 
In certain pharmaceutical dosage forms, the pro-drug form 
of the compounds may be preferred. One of ordinary skill in 
the art will recognize how to readily modifY the present 
30 compounds to pro-drug forms to facilitate delivery of active 
compounds to a targeted site within the host organism or 
patient. The mutineer also will take advantage of favorable 
pharmacokinetic parameters of the pro-drug forms, where 
applicable, in delivering the present compounds to a targeted 
35 site within the host organism or patient to maximize the 
intended effect of the compound. 
Pharmaceutical compositions containing any of the com-
pounds of Formula (I) to Formula (III) or a pharmaceutically 
acceptable salt, solvate, hydrate, prodrug or metabolite 
40 thereof, may be conveniently presented in unit dosage form 
and prepared by any of the methods well known in the art of 
pharmacy. Preferred unit dosage formulations are those con-
taining an effective dose, or an appropriate fraction thereof, of 
the active ingredient, or a pharmaceutically acceptable salt 
45 thereof. The magnitude of a prophylactic or therapeutic dose 
typically varies with the nature and severity of the condition 
to be treated and the route of administration. The dose, and 
perhaps the dose frequency, will also vary according to the 
age, body weight and response of the individual patient. In 
50 general, the total daily dose (in single or divided doses) ranges 
from about 0.1 mg per day to about 7000 mg per day, or about 
0.1 mg per day to about 1 00 mg per day, or from about 1 0 mg 
per day to about 100 mg per day, or from about 20 mg to about 
100 mg, to about 80 mg or to about 60 mg. In some embodi-
55 ments, the total daily dose may range from about 10 mg to 
about 500 mg per day, or about 100 mg to about 500 mg per 
day. It is further recommended that children, patients over 65 
years old, and those with impaired renal or hepatic function, 
initially receive low doses and that the dosage be titrated 
60 based on individual responses and/or blood levels. It may be 
necessary to use dosages outside these ranges in some cases, 
as will be apparent to those in the art. Further, it is noted that 
the clinician or treating physician knows how and when to 
interrupt, adjust or terminate therapy in conjunction with 
65 individual patient's response. 
Alternatively, the maximum safe starting dose of the com-
pounds of the present disclosure for use in initial clinical trials 
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in adults may be determined by following, for example, the 
FDA guidelines for estimating maximum safe dosage. These 
guidelines provide guidance for using the dosages used in 
animal studies to extrapolate safe dosage for use in human 
trials. See Guidance for Industry, Estimating the Maximum 
Safe Starting Dose in Initial Clinical Trials for Therapeutics 
in Adult Healthy Volunteers, Food and Drug Administration, 
Center for Drug Evaluation and Research (CDER), July 2005. 
20 
Route of Administration 
In accordance with the methods of the present disclosure, 
the described halogenated stilbene analogs of the present 
disclosure or a pharmaceutically acceptable salt, solvate, 
hydrate or prodrug thereof, may be administered to a subject 
in a variety of forms depending on the selected route of 
administration, as will be understood by those skilled in the 
art. The active compound of the disclosure may be adminis-
In an embodiment, the amount of compound included 
within therapeutically effective formulations of the present 10 
disclosure is an effective amount for treating the conditions 
associated with MAT2A activity. In general, a therapeutically 
effective amount of the present preferred compound in dos-
age form usually ranges from slightly less than about 0.025 
15 
mg/kg to about 2.5 g/kg, and in certain embodiments about 
2.5 to about 5 mg/kg or about 2.5 to about 100 mg/kg of the 
patient or considerably more, depending upon the compound 
used, the condition being treated and the route of administra-
tion, although exceptions to this dosage range may be con- 20 
templated by the present disclosure. In some embodiments, 
halogenated stilbene analogs of the present disclosure are 
administered in amounts ranging from about 0.1 mg/kg to 
about 100 mg/kg. 
tered, for example, by oral, parenteral, buccal, sublingual, 
nasal, rectal, patch, pump, or transdermal administration and 
the pharmaceutical compositions formulated accordingly. 
Parenteral administration includes intravenous, intraperito-
neal, subcutaneous, intramuscular, intratumoral, transepithe-
lial, nasal, intrapulmonary, intrathecal, rectal and topical 
modes of administration. Parenteral administration may be by 
continuous infusion over a selected period of time 
Alternatively, the compounds of this disclosure may be 
incorporated into formulations for any route of administra-
tion including for example, oral, topical and parenteral 
including intravenous, intramuscular, eye or ocular, intra peri-
toneal, intra buccal, transdermal and in suppository form. 
Methods of Treatment 
In an embodiment, the present disclosure is directed to 
methods for treating a disorder associated with MAT2A bio-
logical activity in a subject comprising administering to the 
subject an effective amount of a compound or composition of 
one or more compounds of formula (I), formula (II) and/or 
formula (III) and/or one or more pharmaceutically acceptable 
The active compound of the present disclosure, i.e., at least 25 
one of the compounds of Formula (1) to Formula (III) or a 
pharmaceutically acceptable salt, solvate, hydrate, prodrug or 
metabolite thereof, is included in the pharmaceutically 
acceptable carrier or diluent in an amount sufficient to deliver 
to a patient a therapeutically effective amount for the desired 30 
indication, without causing serious toxic effects in the patient 
treated. 
salt, solvate, hydrate, prodrug or metabolite thereof. 
In one embodiment, a MAT2A associated disorder is 
tumors and/or cancer. Therefore, in an embodiment, the 
present disclosure is also directed to methods for the treat-
In certain embodiments, the active compound is conve-
niently administered in any suitable unit dosage form, includ-
ing but not limited to one containing 1 to 3000 mg, preferably 
5 to 500 mg of active ingredient per unit dosage form. An oral 
dosage of 10-250 mg is usually convenient. 
The actual dosage amount of a composition of the present 
disclosure administered to a patient or subject can be deter-
mined by physical and physiological factors such as body 
weight, severity of condition, the type of disease being 
treated, previous or concurrent therapeutic interventions, idi-
opathy of the patient and on the route of administration. The 
practitioner responsible for administration will, in any event, 
determine the concentration of active ingredient( s) in a com-
position and appropriate dose(s) for the individual subject. 
In certain embodiments, pharmaceutical compositions 
may comprise, for example, at least about 0.1% of an active 
compound, i.e., at least one of the compounds of Formula (I) 
to Formula (III) or a pharmaceutically acceptable salt, sol-
vate, hydrate, pro drug or metabolite thereof. In other embodi-
ments, the active compound may comprise between about 1% 
to about 7 5% of the weight of the unit, or between about 5% 
to about 50%, for example, and any range derivable therein. In 
other non-limiting examples, a dose may also comprise about 
1 microgram/kg/body weight, about 5 microgram/kg/body 
weight, about 10 microgram/kg/body weight, about 50 
microgram/kg/body weight, about 100 milligram/kg/body 
weight, about 150 milligram/kg/body weight, about 200 mil-
ligram/kg/body weight, about 300 milligram/kg/body 
weight, about 400 milligram/kg/body weight or more per 
administration, and any range derivable therein. In non-lim-
iting examples of a derivable range from the numbers listed 
herein, a range of about 50 microgram/kg/body weight to 
about 50 milligram/kg/body weight, or from about 50 micro-
gram/kg/body weight to about 50 milligram/kg/body weight, 
etc., can be administered. 
35 ment of tumors and/or cancer comprising administering an 
effective amount of one or more halogenated stilbene analogs 
of the present disclosure and/or a pharmaceutically accept-
able salt, solvate, hydrate, prodrug or metabolite thereof to a 
patient in need of such therapy. For example, the present 
40 disclosure contemplates methods of treating various cancers 
and complications thereof. More particularly, the present dis-
closure relates to methods for inhibiting the growth ofbenign 
and malignant cancer, including a malignant tumor or cancer 
comprising exposing the tumor to an inhibitory or therapeu-
45 tically effective amount or concentration of at least one of the 
halogenated stilbene analogs or pharmaceutically acceptable 
salts or pharmaceutically acceptable composition thereof. 
Treatment of internal malignancies such as eye or ocular 
cancer, rectal cancer, colon cancer, cervical cancer, prostate 
50 cancer, breast cancer, liver cancer and bladder cancer, and 
age-related cancer among numerous others are contemplated 
by the present disclosure. 
Accordingly, the compounds and/or compositions of the 
present disclosure are useful for treating animals, and in 
55 particular, mammals, including humans, as patients. Thus, 
humans and other animals, and in particular, mammals, suf-
fering from hyperproliferative disorders, and in particular, 
cancer, or other diseases as disclosed herein, can be treated by 
administering to the patient an effective amount of one or 
60 more of the halogenated stilbene analogs according to the 
present disclosure, or its derivative or a pharmaceutically 
acceptable salt thereof, optionally in a pharmaceutically 
acceptable carrier or diluent, either alone, or in combination 
with other known pharmaceutical agents (depending upon the 
65 disease to be treated). Treatment according to the present 
disclosure can also be by administration of the compounds 
and/or compositions of the present disclosure in conjunction 
US 9,132,102 B2 
21 
with other conventional cancer therapies, such as radiation 
treatment or surgery or administration of other anti-cancer 
agents. 
In certain embodiments, the present disclosure can find 
application in the treatment of any disease for which delivery 
of a therapeutic halogenated stilbene analog or a pharmaceu-
tically acceptable salt, solvate, hydrate, pro drug or metabolite 
thereof to a cell or tissue of a subject is believed to be of 
therapeutic benefit. Examples of such diseases include hyper-
proliferative diseases and quiescent malignant diseases. In 10 
particular embodiments, the disease is a hyperproliferative 
disease, such as cancer of solid tissues or blood cells. Quies-
cent malignant diseases that can be treated by a halogenated 
stilbene analog of the present disclosure or a pharmaceuti-
cally acceptable salt, solvate, hydrate, prodrug or metabolite 15 
thereof include, for example, chronic lymphocytic leukemia. 
22 
TCF/LEF family transcription factors to promote specific 
gene expression. In this aspect of the disclosure, cells are 
brought into contact with an amount of one or more com-
pounds of the disclosure sufficient to disrupt Wnt signaling in 
the cells. 
Combination Therapy 
The active compounds of the present disclosure, i.e., one or 
more compounds offormula (I), formula (II) and/or formula 
(III) and/or one or more pharmaceutically acceptable salt, 
solvate, hydrate, prodrug or metabolite thereof can also be 
mixed with other active materials that do not impair the 
desired action, or with materials that supplement the desired 
action, such as other anticancer agents, and in certain 
instances depending upon the desired therapy or target, anti-
biotics, antifungals, antinflammatories, antiviral compounds 
or other agents having a distinct pharmacological effect. 
The methods and compositions of the present disclosure 
further provide combination therapies which can enhance the 
therapeutic or protective effect of the compounds of the 
present disclosure, and/or increase the therapeutic effect of 
another anti-cancer or anti-hyperproliferative therapy. Thera-
peutic and prophylactic methods and compositions can be 
provided in a combined amount effective to achieve the 
desired effect, such as the killing of a cancer cell and/or the 
For example, a compound or composition of a halogenated 
stilbene analog of the present disclosure or a pharmaceuti-
cally acceptable salt, solvate, hydrate, prodrug or metabolite 
thereof can be administered to treat a hyperproliferative dis- 20 
ease. The hyperproliferative disease may be cancer, leiomyo-
mas, adenomas, lipomas, hemangiomas, fibromas, pre-neo-
plastic lesions (such as adenomatous hyperplasia and 
prostatic intraepithelial neoplasia), carcinoma in situ, oral 
hairy leukoplakia, or psoriasis. 
The cancer may be a solid tumor, metastatic cancer, or 
non-metastatic cancer. In certain embodiments, the cancer 
may originate in the bladder, blood, bone, bone marrow, 
brain, breast, colon, esophagus, duodenum, small intestine, 
large intestine, colon, rectum, anus, gum, head, kidney, liver, 30 
lung, nasopharynx, neck, ovary, prostate, skin, stomach, tes-
25 inhibition of cellular hyperproliferation. This process may 
involve contacting the cells with, for example, a therapeutic 
nucleic acid, such as a chemotherapeutic agent or an inhibitor 
of gene expression, as a second therapy. A tissue, tumor, or 
tis, tongue, or uterus. In certain embodiments, the cancer is 
ovarian cancer. In particular aspects, the cancer may be a 
chemo-resistant cancer, i.e., refractive forms of cancer. 
Diseases other than cancer involving altered physiological 35 
status are also encompassed by the present disclosure. For 
example, it has been shown that diabetes involves underlying 
signaling changes, namely resistance to insulin and failure to 
activate downstream signaling through IRS (Burks D J, White 
M F. Diabetes 2001 February; 50 Suppl1 :S140-5). Similarly, 40 
cardiovascular disease has been shown to involve hypertro-
phy of the cardiac cells involving multiple pathways such as 
the PKC family (Malhotra A. Mol Cell Biochem 2001 Sep-
tember; 225 (1-):97-107). Inflammatory diseases, such as 
rheumatoid arthritis, are known to involve the chemokine 45 
receptors and disrupted downstream signaling (D'Ambrosio 
D J Immunol Methods 2003 February; 273 (1-2):3-13). 
In another aspect of the disclosure, there is provided a 
method for disrupting Wnt signaling in a cell by contacting 
the cell with an effective amount of a halogenated stilbene 50 
analog of the disclosure. The Wnt signaling pathway 
describes a complex network of proteins most well known for 
their roles in embryogenesis and cancer, but also involved in 
normal physiological processes in adult animals. The canoni-
cal Wnt pathway involves a series of events that occur when 55 
Wnt proteins bind to cell-surface receptors of the Frizzled 
family, causing the receptors to activate Dishevelled family 
proteins and ultimately resulting in a change in the amount of 
~-catenin that reaches the nucleus. Dishevelled (DSH) is a 
key component of a membrane-associated W nt receptor com- 60 
plex which, when activated by Wnt binding, inhibits a second 
complex of proteins that includes axin, GSK-3, and the pro-
teinAPC. The axin/GSK -3/ APC complex normally promotes 
the proteolytic degradation of the .beta-catenin intracellular 
signaling molecule. After this ~-catenin destruction complex 65 
is inhibited, a pool of cytoplasmic ~-catenin stabilizes, and 
some ~-catenin is able to enter the nucleus and interact with 
cell can be contacted with the compounds or compositions of 
the present disclosure and one or more additional anti-cancer 
treatment. For example, an additional anticancer treatment 
may include a chemotherapeutic agent, an anti-hormonal 
agent, radiotherapy, surgical therapy, or immunotherapy. 
Examples of chemotherapeutic agents include alkylating 
agents such as thiotepa and cyclosphosphamide; alkyl sul-
fonates such as busulfan, improsulfan and piposulfan; aziri-
dines such as benzodopa, carboquone, meturedopa, and ure-
dopa; ethylenimines and methylamelamines including 
altretamine, triethylenemelamine, trietylenephosphoramide, 
triethiylenethiophosphoramide and trimethylolomelamine; 
acetogenins (especially bullatacin and bullatacinone ); a 
camptothecin (including the synthetic analogue topotecan); 
bryostatin; callystatin; CC-1065 (including its adozelesin, 
carzelesin and bizelesin synthetic analogues); cryptophycins 
(particularly cryptophycin 1 and cryptophycin 8); dolastatin; 
duocarmycin (including the synthetic analogues, KW-2189 
and CB1-TM1); eleutherobin; pancratistatin; a sarcodictyin; 
spongistatin; nitrogen mustards such as chlorambucil, chlor-
naphazine, cholophosphamide, estramustine, ifosfamide, 
mechlorethamine, mechlorethamine oxide hydrochloride, 
melphalan, novembichin, phenesterine, prednimustine, tro-
fosfamide, uracil mustard; nitrosureas such as carmustine, 
chlorozotocin, fotemustine, lomustine, nimustine, andranim-
nustine; antibiotics such as the enediyne antibiotics (e.g., 
calicheamicin, especially calicheamicin gmall and cali-
cheamicin omegall; dynemicin, including dynemicinA; bis-
phosphonates, such as clodronate; an esperamicin; as well as 
neocarzinostatin chromophore and related chromoprotein 
enediyne antiobiotic chromophores, aclacinomysins, actino-
mycin, authrarnycin, azaserine, bleomycins, cactinomycin, 
carabicin, caminomycin, carzinophilin, chromomycinis, dac-
tinomycin, daunorubicin, detorubicin, 6-diazo-5-oxo-L-nor-
leucine, doxorubicin (including morpholino-doxorubicin, 
cyanomorpholino-doxorubicin, 2-pyrrolino-doxorubicin and 
deoxy doxorubicin), epirubicin, esorubicin, idarubicin, mar-
cellomycin, mitomycins such as mitomycin C, mycophenolic 
acid, nogalarnycin, olivomycins, peplomycin, potfiromycin, 
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pounds offormula (I), formula (II) and/or formula (III) and/or 
one or more pharmaceutically acceptable salt, solvate, 
hydrate, prodrug or metabolite thereof, may be administered 
before, during, after or in various combinations relative to a 
second anti -cancer treatment. The administrations may be in 
intervals ranging from concurrently to minutes to days to 
weeks. In embodiments where the halogenated stilbene con-
taining composition is provided to a patient separately from 
an additional anti-cancer agent, one would generally ensure 
that a significant period of time did not expire between the 
time of each delivery, such that the two agents would still be 
able to exert an advantageously combined effect on the 
patient. In such instances, it is contemplated that one may 
provide a patient with the inhibitor of gene expression therapy 
and the anti-cancer therapy within about 12 to 24 or 72 h of 
each other and, more preferably, within about 6-12 h of each 
other. In some situations it may be desirable to extend the time 
period for treatment significantly where several days (2, 3, 4, 
5, 6 or7) to several weeks (1, 2, 3, 4, 5, 6, 7 or 8) lapse between 
respective administrations. 
Within a single day (24-hour period), the patient may be 
given one or multiple administrations of the agent(s). More-
over, after a course of treatment, it is contemplated that there 
is a period of time at which no anti -cancer treatment is admin-
istered. This time period may last 1, 2, 3, 4, 5, 6, 7 days, and/or 
1, 2, 3, 4, 5 weeks, and/or 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 
months or more, depending on the condition of the patient, 
such as their prognosis, strength, health, etc. 
Administration of any compound or therapy of the present 
disclosure to a patient will follow general protocols for the 
administration of such compounds, taking into account the 
toxicity, if any, of the agents. Therefore, in some embodi-
ments there is a step of monitoring toxicity that is attributable 
to combination therapy. It is expected that the treatment 
cycles would be repeated as necessary. It also is contemplated 
that various standard therapies, as well as radiation and sur-
gical intervention, may be applied in combination with the 
described therapy. 
In specific aspects, it is contemplated that a standard 
therapy will include chemotherapy, radiotherapy, immuno-
therapy, surgical therapy or gene therapy and may be 
employed in combination with the combination therapy 
described herein. 
puromycin, quelamycin, rodorubicin, streptonigrin, strepto-
zocin, tubercidin, ubenimex, zinostatin, zorubicin; anti-me-
tabolites such as methotrexate and 5-fluorouracil (5-FU); 
folic acid analogues such as denopterin, methotrexate, 
pteropterin, trimetrexate; purine analogues such as fludara-
bine, 6-mercaptopurine, thiamiprine, thioguanine; pyrimi-
dine analogues such as ancitabine, azacitidine, 6-azauridine, 
carmofur, cytarabine, dideoxyuridine, doxifluridine, enocit-
abine, floxuridine; androgens such as calusterone, dromo-
stanolone propionate, epitiostanol, mepitiostane, testolac- 10 
tone; anti-adrenals such as aminoglutethimide, mitotane, 
trilostane; folic acid replenisher such as frolinic acid; acegla-
tone; aldophosphamide glycoside; aminolevulinic acid; eni-
luracil; amsacrine; bestrabucil; bisantrene; edatraxate; defo-
famine; demecolcine; diaziquone; elformithine; elliptinium 15 
acetate; an epothilone; etoglucid; gallium nitrate; hydrox-
yurea; lentinan; lonidainine; maytansinoids such as may-
tansine and ansamitocins; mitoguazone; mitoxantrone; mopi-
danmol; nitraerine; pentostatin; phenamet; pirarubicin; 
losoxantrone; podophyllinic acid; 2-ethylhydrazide; procar- 20 
bazine; PSK polysaccharide complex); razoxane; rhizoxin; 
sizofiran; spirogermanium; tenuazonic acid; triaziquone; 
2,2',2"-trichlorotriethylamine; trichothecenes (especially T-2 
toxin, verracurin A, roridin A and anguidine); urethan; vin-
desine; dacarbazine; mannomustine; mitobronitol; mitolac- 25 
to!; pipobroman; gacytosine; arabinoside ("Ara-C"); cyclo-
phosphamide; thiotepa; taxoids, e.g., paclitaxel and 
doxetaxel; chlorambucil; gemcitabine; 6-thioguanine; mer-
captopurine; methotrexate; platinum coordination complexes 
such as cisplatin, oxaliplatin and carboplatin; vinblastine; 30 
platinum; etoposide (VP-16); ifosfamide; mitoxantrone; vin-
cristine; vinorelbine; novantrone; teniposide; edatrexate; 
daunomycin; aminopterin; xeloda; ibandronate; irinotecan 
(e.g., CPT-I 1); topoisomerase inhibitor RFS 2000; difluo-
romethylomithine (DMFO); retinoids such as retinoic acid; 35 
capecitabine; cisplatin (CDDP), carboplatin, procarbazine, 
mechlorethamine, cyclophosphamide, camptothecin, ifosfa-
mide, melphalan, chlorambucil, busulfan, nitrosurea, dacti-
nomycin, daunorubicin, doxorubicin, bleomycin, plicomy-
cin, mitomycin, etoposide (VP 16), tamoxifen, raloxifene, 40 
estrogen receptor binding agents, taxol, paclitaxel, docetaxel, 
gemcitabien, navelbine, famesyl-protein tansferase inhibi-
tors, transplatinum, 5-fluorouracil, vincristine, vinblastine 
and methotrexate and pharmaceutically acceptable salts, 
acids or derivatives of any of the above. 45 Articles of Manufacture 
Also included in the formulations may be anti-hormonal 
agents that act to regulate or inhibit hormone action on tumors 
such as anti-estrogens and selective estrogen receptor modu-
lators (SERMs), including, for example, tamoxifen, ralox-
ifene, droloxifene, A-hydroxytamoxifen, trioxifene, keox- 50 
ifene, LY1 17018, onapristone, and toremifene; aromatase 
inhibitors that inhibit the enzyme aromatase, which regulates 
estrogen production in the adrenal glands, such as, for 
example, 4(5)-imidazoles, aminoglutethimide, megestrol 
acetate, exemestane, formestanie, fadrozole, vorozole, letro- 55 
zole, and anastrozole; and anti-androgens such as flutamide, 
nilutamide, bicalutamide, leuprolide, and goserelin; as well 
In another embodiment of the disclosure, an article of 
manufacture, or "kit", containing materials useful for the 
treatment of the diseases and disorders described above is 
provided. In one embodiment, the kit comprises a container 
comprising at least one compound of formula (I)-(III), and/or 
one or more pharmaceutically acceptable salt, solvate, 
hydrate, prodrug or metabolite thereof. 
The kit may further comprise a label or package insert on or 
associated with the container. The term "package insert" is 
used to refer to instructions customarily included in commer-
cial packages of therapeutic products, that contain informa-
tion about the indications, usage, dosage, administration, 
contraindications and/or warnings concerning the use of such 
therapeutic products. Suitable containers include, for 
example, bottles, vials, syringes, blister pack, etc. The con-
tainer may be formed from a variety of materials such as glass 
or plastic. The container may hold a compound of formula 
(I)-(III) or a formulation thereof which is effective for treating 
the condition and may have a sterile access port (for example, 
as troxacitabine (a 1,3-dioxolane nucleoside cytosine ana-
logue); antisense oligonucleotides, particularly those which 
inhibit expression of genes in signaling pathways implicated 60 
in abherant cell proliferation, such as, for example, PKC-
alpha, Raif and H -Ras; ribozymes such as a VEGF expression 
inhibitor and a HER2 expression inhibitor; vaccines such as 
gene therapy vaccines and pharmaceutically acceptable salts, 
acids or derivatives of any of the above. 65 the container may be an intravenous solution bag or a vial 
having a stopper pierceable by a hypodermic injection 
needle). At least one active agent in the composition is a 
In an embodiment, a therapeutic formulation or composi-
tion set forth herein, which comprises one or more com-
US 9,132,102 B2 
25 
compound of formula (I)-(III). The label or package insert 
indicates that the composition is used for treating the condi-
tion of choice, such as cancer. 
In an embodiment, the kit includes two separate pharma-
ceutical compositions: one containing a compound of the 
present disclosure, and a second pharmaceutical compound. 
In another embodiment, an assay or diagnostic kit includes a 
labeled compound of the present disclosure and one or more 
reagents necessary for detecting the labeled compound upon 
binding to its target in-vivo or in-vitro. In a related embodi- 10 
ment, the kit includes a package insert that describes the steps 
necessary for carrying out the detection assay. 
In another embodiment, a kit of the disclosure further 
comprises a needle or syringe, preferably packaged in sterile 
15 
form, for injecting the composition, and/or a packaged alco-
hol pad. Instructions are optionally included for administra-
tion of halogenated stilbene compounds by a clinician or by 
the patient. 
26 
the art can select the linker moiety of the compounds of the 
present disclosure in order to provide additional specificity of 
them for MAT2A. 
Linker moieties include among others, ethers, polyethers, 
diamines, ether diamines, poly ether diamines, amides, polya-
mides, polythioethers, disulfides, silyl ethers, alkyl or alkenyl 
chains (straight chain or branched and portions of which may 
be cyclic) aryl, diary! or alkyl-aryl groups, having from 0 to 3 
sites of aliphatic unsaturation. While normally amino acids 
and oligopeptides are not preferred, when used they will 
normally employ amino acids of from 2-3 carbon atoms, i.e. 
glycine and alanine. Aryl groups in linker moieties can con-
tain one or more heteroatoms (e.g., N, 0 or S atoms). The 
number of atoms referred to above are exclusive of hydrogen 
in referring to the number of atoms in a group, unless indi-
cated otherwise. The linker moieties, when other than a bond, 
will have from about 1 to 60 atoms, usually 1 to 30 atoms, 
where the atoms include C, N, 0, S, P, etc., particularly C, N 
and 0, and will generally have from about 1 to 12 carbon 
Diagnostic Methods and Diagnostic Probes 20 atoms and from about 0 to 8, usually 0 to 6 heteroatoms. 
Another aspect of the present disclosure provides com-
pounds having general formulas (I)-(III) with a linker moiety 
(hydrophobic linkers, hydrophilic linkers, photo-cleveable 
linkers, redox reaction-cleveable linkers), wherein the linker 
moiety is covalently bonded to a label molecule (a label could 25 
be a fluorophor, biotin, different polymer beads and different 
reactive groups). Exemplary biotinylated analogs have been 
depicted in FIG. 4 and synthesized according to Example 3, 
below. 
In an embodiment, it is desirable to have a detectable label 
associated with a compound of the present disclosure to allow 
the compound-MAT2A complex to be captured and washed 
free of other components of the reaction mixture. The label 
will generally be under about 1 kDa. Biotin is a conventional 
label or ligand, particularly analogs such as dethiobiotin and 
deiminobiotin, which can be readily displaced from strepta-
vidin by biotin. However, any small molecule will suffice that 
can be captured and released under convenient conditions. 
Affinity purification of biological molecules, for example 
proteins, is known in the art and allows the purification of 
molecules by exploiting the binding affinity of the target 
molecule for a molecular binding partner. Examples of affin-
ity purification methods are fusion tag protein purification, 
35 avidin-biotin system, pull-down assay and the like. 
The compounds of the present disclosure when biotiny- 30 
lated provide suitable means for non-radioactive detection 
and quantitation of MAT2A from complex samples, which 
offer a useful alternative approach to the routinely used radio-
metric assays. Therefore, another aspect of the present dis-
closure relates to the use ofbiotinylated stilbene analogs as a 
diagnostic reagent for detecting or monitoring the presence or 
levels MAT2A in a complex protein sample. A complex pro-
tein sample contains multiple proteins, and may additionally 
contain other contaminants. Non-limiting examples of a com-
plex protein sample include tumor tissues, biopsy, serum and 
cell extracts. 
In another embodiment, the present disclosure relates to a 
method of diagnosing cancer in a subject, comprising: (1) 
contacting a labeled compound of formula (I)-(III) with pro-
tein in a complex protein sample obtained from the patient to 
40 bind the compound to and detect MAT2A protein in the 
sample; and (2) comparing the level ofMAT2A in the sample 
to that in a normal reference sample, whereupon if the level of 
MAT2A in the sample is statistically higher than that in the 
normal reference sample, a diagnosis of cancer is indicated. 
In one embodiment, the present disclosure relates to a 
method of detecting, monitoring or analyzing the levels of 
MAT2A in a complex protein sample, said method compris-
ing adding a labeled compound of formula (I)-(III) to said 
complex protein mixture under conditions whereby said 
labeled compound covalently conjugates to MAT2A; isolat-
ing the conjugated MAT2A by a suitable affinity-based sepa-
ration method, removing unbound proteins, detecting the 
level of MAT2A following the separation. In a related 
embodiment, the detection can be accomplished by measur-
ing a fluorescence signal emitted from the compound of for-
mula (I)-(III). In another related embodiment, the detection 
can be accomplished by measuring a fluorescence signal 
emitted from a label bound via a linker to the compound of 
formula (1)-(III). The detection step can also be accom-
plished using various analytical procedures that known to the 
artisan for separating and analyzing complex protein mix-
tures. These analytical procedures include chromatographic 
methods such as HPLC, FPLC, ion exchange, size exclusion, 
mass spectrometry, and the like. 
The linker moiety that can be used to attach a detectable 
label to the compounds of the present disclosure can be any of 
the linkers shown in FIG. 4. Alternatively, the linker moiety 
can a linker moiety comprising a repeating alky leneoxy struc-
ture (polyethylene glycols, or "PEG"). Thus, one of skill in 
45 In a related embodiment, the sample is a biopsy sample con-
taining, for example, cancer cells selected from breast, pros-
tate, colorectal, lung, colon, bladder, head and neck, intestine, 
ovarian, or skin cancer cells. 
In another embodiment, the present disclosure relates to a 
50 method of identifYing a subject who is a candidate for receiv-
ing treatment with the compounds of the present disclosure; 
such method comprises (1) obtaining a protein sample from 
the subject, (2) contacting a detectably labeled compound of 
formula (I)-(III) with protein present in a complex protein 
55 sample to bind to and detect MAT2A in said sample; and (3) 
comparing the level of MAT2A in the sample to that present 
in a normal reference sample, whereupon if the level of 
MAT2A in the sample is statistically higher than that in the 
normal reference, the subject's candidacy for treatment with 
60 one or more compounds of the present disclosure is indicated. 
In a related embodiment, the protein sample is a biopsy 
sample, tissue sample, serum sample, urine sample and the 
like. If necessary, conventional tools such as protein isolation 
kits can be used to obtain protein samples from raw biopsy, 
65 tissue, blood or urine samples. In another related embodi-
ment, the labeled compound is a biotinylated compound of 
formula (I)-(III). 
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EXAMPLES 
The following examples are intended to further illustrate 
certain preferred embodiments of the disclosure and are not 
limiting in nature. Those skilled in the art will recognize, or be 5 
able to ascertain, using no more than routine experimentation, 
numerous equivalents to the specific substances and proce-
dures described herein. 
Example 1 10 
Synthesis of Stilbene Analogs 
Materials and Methods: 
28 
chromatographed using 1:10 CH3 0H:CH2 Cl2 to afford 85 
mg (43%) of 4a. mp 184-185° C. 
Synthesis of(E)-4-Methoxystilbene (4b) 
Procedure B. Yield 87%. Colorless crystals: mp 136-137° 
C. 
Synthesis of (E)-4-(2-Fluorostyryl)-N,N-dimethyla-
niline (4e) 
Procedure B. Yield 84%. Light yellow crystals from aceto-
nitrile. mp 124-126° C. 1H NMR (acetone-d6 ): o 7.73-7.68 
(m, lH), 7.46 (d, 2H, 1=8.8 Hz), 7.26-7.09 (m, 4H), 7.08 (d, 
15 lH, 1=16.8 Hz), 6.75 (d, 2H, 1=9.2 Hz), 2.98 (s, 6H). 13C 
NMR (acetone-d6 ): o160.18 (d, 1=245.9 Hz), 150.85, 131.67 
(d, 1=4.6 Hz), 128.08 (d, 1=8.4 Hz), 127.93 (two C), 126.8 (d, 
1=4.5 Hz), 126.14 (d, 1=12.1 Hz), 125.46, 124.59 (d, 1=3.1 
Hz), 115.64 (d, 1=22.0 Hz), 115.49 (d, 1=4.6 Hz), 112.44 (two 
Chemicals were purchased from Sigma Aldrich, MP Bio-
medical ( 4c) or TCI ( 4d) or were synthesized according to 
literature procedures. Solvents were used from commercial 
vendors without further purification unless otherwise noted. 
Nuclear magnetic resonance spectra were determined using a 
Varian instrument (lH, 400 MHz; 13C, 100 MHz unless 
otherwise noted). LRMS electron-impact (EI) ionization 
mass spectra were recorded at 70 eV on a ThermoFiunigan 
PolarisQ (ion trap mass spectrometer). Samples were intro-
duced via a heatable direct probe inlet. High resolution elec- 25 
tron impact (EI) ionization mass spectra were recorded at 25 
20 C), 39.69 (two C). MS: m/z (%) 241 (100), 240 (74), 225 (32), 
197 (20), 196 (20), 177 (18), 176 (13). Anal. Calcd for 
C16H16FN: C, 79.64; H, 6.68. Found: C, 79.77; H, 6.80. 
eV on a JEOL 1MS-700T MStation (magnetic sector instru-
ment) at a resolution of greater than 10,000. Samples were 
introduced via heatable direct probe inlet. Perfluorokerosene 
(pfk) was used to produce reference masses. MALDI mass 30 
spectra were obtained on a Bruker Utraflexstreme time-of-
flight mass spectrometer (Billerica, Mass.), using DHB (2,5-
dihydroxybenzoic acid) matrix. Purity of compounds was 
>95% as established by combustion analyses. Elemental 
analyses were determined by Atlantic Microlabs, Inc., Nor- 35 
cross, Ga. Compounds were chromatographed on preparative 
layer Merck silica gel F254 unless otherwise indicated. 
General Procedure A. 
To 1.5 mmol oftriphenylphosphonium bromide suspended 
in 4 mL of anhydrous THF at -78° C. was added 2.25 mmol 40 
(1.5 eq) of n-BuLi (1.6M in hexane). See FIG. 2 for a general 
schematic diagram of this reaction. The mixture was allowed 
to warm to 25° C. for 30 min, and 2.25 mmol of an aldehyde 
in 1 mL of anhydrous THF was added. The mixture was 
stirred for 24 h, diluted with CH2 Cl2 , washed with saturated 45 
NH4 Cl solution, and dried over anhydrous MgS04 . The prod-
uct was purified by chromatography and/or recrystallization 
as noted for individual stilbenes listed below. 
Synthesis of (E)-4-(3-Fluorostyryl)-N,N-dimethyla-
niline ( 4f) 
Procedure B. Yield 65%. Light yellow crystals from aceto-
nitrile. mp 147-148° C. 1H NMR (acetone-d6): o7.42 (d, 2H, 
1=8.4 Hz), 7.35-7.25 (m, 3H), 7.17 (d, lH, 1=16.4 Hz), 6.96 
(d, lH, 1=16.8Hz), 6.93-6.88 (m, lH), 6.72 (d, 2H, 1=8.8 Hz), 
2.95 (s, 6H). 13C NMR (acetone-d6 ): o163.47 (d, 1=241.4 
Hz), 150.82, 141.36 (d, 1=7.6 Hz), 130.66, 130.42 (d, 1=8.4 
Hz), 127.97 (two C), 125.22, 122.63 (d, 1=2.2 Hz), 122.24 (d, 
1=2.2 Hz), 113.12 (d, 1=21.3 Hz), 112.43 (two C), 111.96 (d, 
1=22.0 Hz), 39.69 (two C). MS: m/z (%) 241 (100), 240 (69), 
225 (25), 197 (20), 196 (18), 177 (16), 176 (1 0). Anal. Calcd 
for C16H16FN: C, 79.64; H, 6.68. Found: C, 79.86; H, 6.67. 
Synthesis of (E)-4-( 4-Fluorostyryl)-N,N-dimethyla-
niline (4g) 
Procedure B. Yield 64%. Light yellow crystals from aceto-
nitrile. mp 197-198° C. Anal. CalcdforC16H16FN: C, 79.64; 
H, 6.68. Found: C, 79.85; H, 6.64. 
Synthesis of (E)-4-(2-Fluorostyryl)-N,N-diethyla-
niline ( 4h) 
General Procedure B. Procedure B. Yield 51%. Light yellow crystals from hex-
Toasolutionof1.5mmolofdiethylphosphonatein4mL 50 ane. mp 78-79° C. 1H NMR (acetone-d6): 07.69-7.65 (m, 
of anhydrous DMF at oo C. was added 2.25 mmol (1.5 eq) of lH), 7.40 (d, 2H, 1=8.8 Hz), 7.24-7.08 (m, 4H), 7.04 (d, lH, 
NaH (washed with hexanes to remove oil). See FIG. 2 for a 1=16.4 Hz), 6.71 (d, 2H, 1=8.8 Hz), 3.42 (q, 4H, 1=7.2 Hz), 
general schematic diagram of this reaction. The mixture was 1.16 (t, 6H, 1=7.2 Hz). 13C NMR (acetone-d6 ): o160.13 (d, 
stirred for 20 min, and 1.5 mmol of an aldehyde in 1 mL of 1=242.2 Hz), 148.04, 131.73 (d, 1=4.5 Hz), 128.24 (two C), 
anhydrous DMF was added dropwise. The mixture was 55 127.91 (d, 1=7.6 Hz), 126.70 (d, 1=4.5 Hz), 126.27 (d, 1=11.4 
stirred 24 h at 25° C., quenched with ice, extracted with Hz), 124.57 (d, 1=3.8 Hz), 124.49, 115.62 (d, 1=22.0 Hz), 
CH2 Cl2 , and dried over anhydrous MgS04 . The product was 114.82 ( d, 1=3.8 Hz), 111.76 (two C), 44.19 (two C), 12.21 
purified by chromatography and/or recrystallization as noted (two C). MS: m/z (%) 269 (34), 255 (19), 254 (100), 226 (22), 
for individual stilbenes listed below. 225 (20), 197 (16), 196 (17). Anal. Calcd for C18H20FN: C, 
60 80.26; H, 7.48. Found: C, 80.07; H, 7.61. 
Synthesis of (E)-4-Hydroxystilbene ( 4a) 
To 210 mg (1 mmol) of (E)-4-methoxystilbene ( 4b) in 7 
mL ofCH2 Cl2 was added 1.28 mL oflM BBr3 (1.3 mmol) in 
dichloromethane at -1 oo C. The mixture was stirred for 4 hat 65 
-5° C. and quenched by pouring into cold water. The product 
was extracted with CH2Cl2 , dried over anhydrous MgS04 and 
Synthesis of (E)-4-(2-Fluorostyryl)-N,N-diphenyla-
niline ( 4i) 
Procedure B. Yield 60%. Light yellow crystals from hex-
ane. mp 114-115° C. 1H NMR (acetone-d6 ): 07.77-7.73 (m, 
lH), 7.54 (d, 2H, 1=8.4 Hz), 7.34-7.06 (m, 15H), 7.02 (d, 2H, 
US 9,132,102 B2 
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1=8.8 Hz). 13C NMR (acetone-d6): o160.39 (d, 1=245.9 Hz), 
148.00, 147.73, 131.58, 130.87 (d, 1=4.5 Hz), 129.63, 128.90 
(d, 1=8.3 Hz), 127.88, 127.23 (d, 1=3.8 Hz), 125.58 (d, 1=12.0 
Hz), 124.75, 124.71, 123.53, 123.25, 118.78 (d, 1=3.8 Hz), 
115.76 (d, 1=22.0 Hz). MS: m/z (%) 365 (100), 364 (12), 254 5 
(13).Anal. CalcdforC26H20FN: C, 85.45; H, 5.52. Found: C, 
85.59; H, 5.69. 
30 
(78), 243 (25), 214 (16), 195 (16). Anal. Calcd for 
C16H15F2N: C, 74.11; H, 5.83. Found: C, 74.01; H, 5.71. 
Synthesis of (E)-4-(2,4-Difluorostyryl)-N,N -dim-
ethylaniline (4n) 
Synthesis of (E)-1-( 4-(2-Fluorostyryl)phenyl)-4-
methylpiperazine ( 4j) 
Procedure B. Yield 65%. Light yellow crystals from aceto-
nitrile. mp 142-144° C. 1H NMR (acetone-d6): 07.72-7.69 
(m, lH), 7.48 (d, 2H, 1=8.8 Hz), 7.28-7.09 (m, 5H), 6.96 (d, 
2H, 1=8.8 Hz), 3.22 (t, 4H, 1=5.2 Hz), 2.48 (t, 4H, 1=5.2 Hz), 
2.54 (s, 3H). 13C NMR (acetone-d6 ): o 160.27 (d, 1=245.2 
Hz), 151.59, 131.34 (d, 1=5.3 Hz), 128.42 (d, 1=8.4 Hz), 
127.97, 127.81 (two C), 126.98 (d, 1=3.8 Hz), 125.90 (d, 
1=12.1 Hz), 126.62 (d, 1=3.8 Hz), 116.85 (d, 1=3.8 Hz), 
115.69 (d, 1=22.0 Hz), 115.46 (two C), 55.09 (two C), 48.34 20 
(two C), 45.70. MS: m/z (%) 296 (100), 281 (42), 226 (24), 
211 (46), 197 (28), 196 (42), 177 (28). Anal. Calcd for 
C19H21FN2 : C, 77.00; H, 7.14. Found: C, 77.22; H, 7.49. 
Procedure B. Yield 58%. Yellow crystals from acetonitrile. 
mp 139-140° C. 1HNMR (acetone-d6): 07.78-7.72 (m, lH), 
7.44 (d, 2H, 1=8.4 Hz), 7.17 (d, lH, 1=16.4 Hz), 7.04-6.97 (m, 
3H), 6.75 (d, 2H, 1=9.2 Hz), 2.98 (s, 6H). 13C NMR (acetone-
10 d6): o 161.65 (dd, 11=245.2 Hz, 12=12.1 Hz), 160.00 (dd, 
11=248.6 Hz, 12=12.1 Hz) 150.87, 131.54 (dd, 11=4.5 Hz, 
12=2.3 Hz), 127.89 (two C), 125.34,122.84 (dd, 11=12.1 Hz, 
12=3.8 Hz), 114.56 (t, 1=1.6 Hz), 112.43 (two C), 111.73 (dd, 
11=21.3 Hz, 12 =3.8 Hz, two C), 103.85 (t, 1=26.2 Hz), 39.68 
15 (two C). MS: m/z (%) 259 (100), 258 (71), 243 (30), 215 (15), 
195 (14). Anal. Calcd for C16H15F2 N: C, 74.11; H, 5.83. 
Found: C, 74.25; H, 5.77. 
Synthesis of (E)-4-(2-Fluorostyryl)-N,N-dimethyl-
naphthalen-1-amine ( 4k) 
Procedure B. Yield 18%. Yellow crystals from hexane: 
Et2 0. mp 56-58° C. 
1H NMR (acetone-d6 ): o 8.33-8.27 (m, 
2H), 8.09 (d, lH, 1=16.4 Hz), 7.95-7.91 (m, lH), 7.80 (d' lH' 
1=8.0 Hz), 7.58-7.52 (m, 2H), 7.36-7.15 (m, 4H), 7.28 (d, lH, 
1=16.4 Hz), 2.90 (s, 6H). 13C NMRm (acetone-d6 ): o160.49 
Synthesis of (E)-4-(2,5-Difluorostyryl)-N,N -dim-
ethy !aniline ( 4o) 
Procedure A. Yield 77%. Yellow crystals. mp 146-147° C. 
1H NMR (acetone-d6): o 7.51-7.46 (m, 3H), 7.28 (d, 1H, 
1=16.4 Hz), 7.18-7.12 (m, lH), 7.03 (d, lH, 1=16.4 Hz), 
25 7.00-6.95 (m, lH), 6.76 (d, 2H, 1=8.8 Hz), 2.99 (s, 6H). 13C 
NMR (acetone-d6 ): o 159.28 (dd, 1=236.0 Hz), 156.22 (dd, 
1=241.4 Hz), 151.09, 133.04 (d, 1=3.8 Hz), 128.21 (two C), 
124.94, 116.97 (dd, 11=25.5 Hz, 12=9.6 Hz, two C), 114.08 
(dd, 11=24.7 Hz, 12 =8.7 Hz, two C), 112.38 (two C), 112.12 
30 (d, 1=4.5 Hz), 39.64 (two C). MS: m/z (%) 259 (100), 258 
(84), 243 (29), 215 (18), 195 (17). Anal. Calcd for 
C16H15F2N: C, 74.11; H, 5.83. Found: C, 74.63; H, 5.90. 
(d, 1=246.7 Hz), 151.66, 132.85, 129.41, 129.10 (d, 1=8.4 
Hz), 128.92, 128.38 (d, 1=4.6 Hz), 127.67 (d, 1=3.8 Hz), 
126.27, 125.78 (d, 1=12.2 Hz), 125.17, 124.92, 124.74 (d, 35 
1=3.0 Hz), 124.25, 124.03, 121.75 (d, 1=3.8 Hz), 115.78 (d, 
1=22.0 Hz), 114.19, 44.62. MS: m/z (%) 291 (100), 290 (28), 
276 (70), 261 (40), 247 (22), 246 (15). Anal. Calcd for 
C20H18FN: C, 82.45; H, 6.23. Found: C, 82.42; H, 6.22. 
Synthesis of (E)-2-(2,6-Difluorostyryl)-N,N -dim-
ethy !aniline ( 4 p) 
Procedure B. Yield 92%. Yellow oil. 1 H NMR (acetone-d6): 
o7.78 (d, lH, 1=16.8 Hz), 7.65 (dd, lH, 11=7.6 Hz, 12=1.6 
Hz), 7.36-7.26 (m, 2H), 7.12-7.03 (m, 5H), 2.74 (s, 6H). 13C 
Synthesis of (E)-2-( 4-(2-Fluorostyryl)phenyl)-1-
methyl-lH-imidazole (41) 
Procedure B. Yield 47%. Colorless crystals from hexane. 
mp 60-61° C. 1H NMR (acetone-d6 ): 07.82-7.78 (m, lH), 
7.65 (d, lH, 1=16.0 Hz), 7.35-7.29 (m, lH), 7.26 (d, lH, 
1=16.0 Hz), 7.22-7.13 (m, 2H), 7.08 (d, lH, 1=1.2 Hz), 6.96 
40 NMR (acetone-d6): o161.06 (dd, 11=242.2 Hz, 12=7.6 Hz, 
two C), 152.77, 133.81 (t, 1=8.0 Hz), 131.25, 129.19, 128.59 
(t, 1=11.0 Hz), 126.72, 122.65, 118.46, 115.31 (t, 1=15.6 Hz), 
113.84, 111.92 (dd, 11=19.4 Hz, 12 =6.8 Hz, two C), 44.31 
(two C). MS: m/z (%) 259 (100), 258 (14), 132 (8). Anal. 
45 CalcdforC16H15F2N: C, 74.11; H, 5.83. Found: C, 74.38; H, 
5.79. 
(d, 1H, 1=0.8 Hz), 3.81 (s, 3H). 13C NMR (acetone-d6 ): o 
160.65 (d, 1=246.7 Hz), 145.39, 129.53 (d, 1=8.3 Hz), 128.89, 
127.66 (d, 1=3.0 Hz), 124.98 (d, 1=11.4 Hz), 124.71 (d, 1=3.8 50 
Hz), 122.73 (d, 1=3.8 Hz), 122.18, 116.99 (d, 1=5.3 Hz), 
115.83 ( d, 1=22.0 Hz), 32.04. MS: m/z (%) 202 (17), 201 (59), 
186 (20), 183 (100), 168 (25), 146 (16), 128 (17).Anal. Calcd 
forC 12H11FN2 : C, 71.27; H, 5.48. Found: C, 71.24; H, 5.61. 
Synthesis of (E)-3-(2,6-Difluorostyryl)-N,N -dim-
ethylaniline (4q) 
Procedure B. Yield 53%. Colorless crystals from hexane. 
mp 69-71 o C. 1H NMR (acetone-d6 ): o 7.38 (d, lH, 1=16.8 
Hz), 7.33-7.26 (m, lH), 7.21-7.18 (m, lH), 7.11 (d, lH, 
1=17.2 Hz), 7.07-7.00 (m, 2H), 6.93-6.91 (m, 2H), 6.72-6.69 
Synthesis of (E)-4-(2,3-Difluorostyryl)-N,N-dim-
ethylaniline (4m) 
Procedure A. Yield 88%. Yellow crystals. mp 132-133° C. 
1H NMR (acetone-d6): o 7.50-7.43 (m, 3H), 7.24 (d, 1H, 
1=16.4 Hz), 7.16-7.07 (m, 2H), 7.03 (d, lH, 1=16.4 Hz), 6.73 
55 (m, 1H), 2.96 (s, 6H). 13C NMR (acetone-d6): o161.03 (dd, 
11=248.2 Hz, 12=7.6 Hz, two C), 151.38, 138.03, 136.83 (t, 
1=8.0 Hz), 129.46, 128.70 (t, 1=11.0 Hz), 114.87 (t, 1=16.0 
Hz), 114.81, 114.09, 112.98, 111.91 (dd, 1 1=19.4 Hz, 12=6.5 
Hz, two C), 111.21,39.93 (two C). MS: m/z (%) 259 (100), 
60 258 (52), 239 (31), 238 (33), 223 (16), 222 (37).Anal. Calcd 
forC 16H15F2 N: C, 74.11; H, 5.83. Found: C, 74.30; H, 5.78. 
(d, 2H, 1=8.8 Hz), 2.96 (s, 6H). 13C NMR (acetone-d6 ): o 
151.09, 151.02 (dd, 11=243.6 Hz, 12=12.9 Hz), 147.87 (dd, 
11=246.3 Hz, 12 =12.9 Hz) 133.18 (d, 1=5.3 Hz), 128.19 (two 
C), 124.95,124.56 (dd, 11=7.6 Hz, 12=4.5 Hz, two C), 121.78 65 
(t, 1=3.0 Hz), 114.65 (d, 1=17.4 Hz), 114.24 (t, 1=3.8 Hz), 
112.38 (two C), 39.64 (two C). MS: m/z (%) 259 (100), 258 
Synthesis of (E)-4-(2,6-Difluorostyryl)-N,N -dim-
ethylaniline (4r) 
Procedure B. Yield 94%. Pale yellow crystals from hexane. 
mp 112-113° C. 1HNMR (acetone-d6): o7.45 (d, 2H, 1=8.4 
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Hz), 7.35 (d, lH, 1=16.8 Hz), 7.27-7.20 (m, lH), 7.01-6.98 
(m, 2H), 6.91 (lH, d, 1=16.8 Hz), 6.75 (d, 2H, 1=9.2 Hz), 2.98 
32 
(s, 6H). 13C NMR (acetone-d6): o160.82 (dd, 11=247.9 Hz, 
12=8.0 Hz, two C), 151.10, 135.99 (t, 1=8.3 Hz), 127.97 (two 
C), 127.57 (t, 1=11.3 Hz), 125.41, 115.50 (t, 1=16.0 Hz), 5 
112.40 (two C), 111.79 (dd, 11=19.0 Hz, 12 =6.8 Hz, two C), 
109.73,39.65 (two C). MS: m/z (%) 259 (100), 258 (71), 243 
(25), 195 (ll).Anal. CalcdforC16H15F2N: C, 74.11; H, 5.83. 
Found: C, 74.08; H, 5.79. 
1=8.8 Hz), 7.29 (d, lH, 1=16.8 Hz), 6.91 (t, 2H, 1=8.8 Hz), 
6.83 (d, lH, 1=16.8 Hz), 6.75 (d, 2H, 1=8.8 Hz), 2.99 (s, 6H). 
13C NMR (acetone-d6): o160.87 (m, three C), 151.09, 135.59 
(m, two C), 127.95 (two C), 125.25, 112.39 (two C), 108.80, 
100.65 (dd, 11=30.7 Hz, 12 =25.8 Hz, two C), 39.64 (two C). 
MS: m/z (%) 277 (100), 276 (75), 261 (29). Anal. Calcd for 
C16H14F3N: C, 69.30; H, 5.09. Found: C, 69.49; H, 4.99. 
Synthesis of (E)-4-(2-chloro-6-fluorostyryl)-N,N-
dimethylaniline (4x) Synthesis of (E)-4-(2,6-Difluorostyryl)-N,N-diethy-
laniline ( 4s) 
Procedure B. Yield 57%. Yellow crystals from hexane. mp 
70-71° C. 1H NMR (acetone-d6): o7.43 (d, 2H, 1=8.4 Hz), 
7.34 (d, lH, 1=16.8 Hz), 7.27-7.20 (m, lH), 7.01-6.98 (m, 
2H), 6.89 (d, lH, 1=16.8 Hz), 6.72 (d, 2H, 1=8.8 Hz), 3.43 (q, 
4H, 1=7.2 Hz), 1.16 (t, 6H, 1=7.2 Hz). 13CNMR(acetone-d6): 
o160.80(dd,11=247.1 Hz,12=8.0Hz, two C), 148.30,136.07 
(t, 1=8.3 Hz), 128.29 (two C), 127.37 (t, 1=10.6 Hz), 124.45, 
115.62 (t, 1=16.0 Hz), 111.78 (dd, 11 =19.0 Hz, 12 =6.8 Hz, two 
C), 111.73 (two C), 109.07, 44.20 (two C), 12.20 (two C). 
MS: m/z (%) 287 ( 44), 272 (1 00), 244 (21 ), 243 (15). Anal. 
CalcdforC18H19F2N: C, 75.24; H, 6.66. Found: C, 75.12; H, 
6.79. 
Synthesis of (E)-4-(3,4-Difluorostyryl)-N,N-dim-
ethylaniline ( 4t) 
Procedure A. Yield 59%. Yellow crystals from hexane. mp 
159-160° C. 1HNMR (acetone-d6): 07.50-7.44 (m, !H), 7.41 
(d, 2H, 1=8.8 Hz), 7.32-7.28 (m, lH), 7.27-7.20 (m, lH), 7.11 
(d, lH, 1=16.0 Hz), 6.92 (d, lH, 1=16.4 Hz), 6.71 (d, 2H, 
1=8.8 Hz), 2.95 (s, 6H). 13C NMR (acetone-d6): o 150.82, 
150.56 (dd, 11=243.9 Hz, 12=12.9 Hz), 148.99 (dd, 11=244.3 
Hz, 12=12.9 Hz), 130.55 (d, 1=3.0 Hz), 127.91 (two C), 
125.16, 122.71 (d, 1=6.1 Hz), 122.68 (d, 1=6.1 Hz), 121.68 (d, 
1=2.3 Hz), 117.49 (d, 1=17.4 Hz), 113.96 (d, 1=17.5 Hz), 
112.43 (two C), 39.68 (two C). MS: m/z (%) 259 (100), 258 
(82), 243 (36), 215 (22), 195 (16). Anal. Calcd for 
C16H15F2N: C, 74.11; H, 5.83. Found: C, 74.24; H, 5.79. 
Synthesis of (E)-4-(3,5-Difluorostyryl)-N,N-dim-
ethylaniline (4u) 
Procedure A. Yield 51%. Yellow crystals. mp 136-137° C. 
10 
Procedure B. Yield 90%. Yellow crystals, crystals from 
hexane. mp 42-44° C. 1H NMR (DMSO-d6): o7.43 (d, 2H, 
15 
1=8.8 Hz), 7.36-7.33 (m, lH), 7.27-7.13 (m, 3H), 6.94 (d, lH, 
1=16.8 Hz), 6.73 (d, 2H, 1=8.8 Hz), 2.95 (s, 6H). 13C NMR 
(DMSO-d6): o 160.74 (d, 1=249.1 Hz), 151.02, 136.87 (d, 
1=12.1 Hz), 133.35 (d, 1=6.1 Hz), 128.51 (d, 1=10.1 Hz), 
128.31 (two C), 126.28 (d, 1=3.4 Hz), 124.72, 124.59 (d, 
20 1=14.8 Hz), 115.55 (d, 1=23.5 Hz), 113.91 (d, 1=2.1 Hz), 
112.58 (two C), 40.30 (two C). MS: m/z (%) 277 (37), 276 
(36), 275 (100), 274 (31), 225 (19).Anal. Calcdfor C16H15Cl 
FN: C, 69.69; H, 5.48. Found: C, 69.68; H, 5.61. 
25 Synthesis of (E)-4-(2,6-dichlorostyryl)-N,N-dim-
ethylaniline (4y) 
Procedure B. Yield 78%. Yellow crystals from hexane. mp 
96-97° C. 1H NMR (acetone-d6): 7.48-7.44 (m, 4H), 7.25-
30 7.21 (m, lH), o7.11 (d, lH, 1=16.8 Hz), 6.94 (d, lH, 1=16.4 
Hz), 6.77 (d, 2H, 1=8.8 Hz), 2.99 (s, 6H). 13C NMR (acetone-
d6): o151.19, 137.63, 135.36, 134.18,128.97 (two C), 128.18 
(two C), 128.02 (two C), 124.79, 117.40, 112.41 (two C), 
39.68 (two C). MS: m/z (%) 293 (65), 292 (32), 291 (100), 
35 221 (40), 220 (30).Anal. Calcdfor C16H15Cl2N: C, 65.77; H, 
5.17. Found: C, 65.52; H, 5.17. 
40 
Synthesis of (E)-4-(2,6-Difluorophenethyl)-N,N-
dimethylaniline (5r) 
Anal. Calcd for C16H15F2N: C, 74.11; H, 5.83. Found: C, 45 
74.38; H, 5.70. 
To 150 mg (0.58 mmol) of 4r in 10 mL ofTHF was added 
50 mg of 10% Pd-C. The mixture was hydrogenated at 40 
psi on a Parr shaker for 5 h. The mixture was filtered through 
Celite and chromatographed using 1: 10 EtOAc :hexane to 
afford 110 mg (7 6%) of 5r: Colorless crystals from hexane. 
mp 42-43° C. 1H NMR (acetone-d6): o 7.31-7.23 (m, lH), 
Synthesis of (E)-N,N-Dimethyl-4-(2,3,6-trifluo-
rostyryl)aniline (4v) 
Procedure B. Yield 45%. Light yellow crystals from hex-
ane. mp 91-92° C. 1HNMR(acetone-d6): o7.48 (d, 2H, 1=9.2 
Hz), 7.39 (d, lH, 1=16.8 Hz), 7.22-7.14 (m, lH), 7.06-7.00 
(m, lH), 6.89 (d, lH, 1=16.8 Hz), 6.76 (d, 2H, 1=8.0 Hz), 3.00 
7.02 (d, 2H, 1=8.4 Hz), 6.98-6.92 (m, 2H), 6.66 (d, 2H, 1=8.4 
Hz), 2.90-2.89 (m, 2H), 2.85 (s, 6H), 2.77-2.73 (m, 2H). 13C 
NMR (acetone-d6): o161.68 (dd, 11=244.1 Hz, 12 =8.7 Hz, 
50 two C), 149.62, 128.98, 128.94 (two C), 128.15 (t, 1=10.3 
Hz), 117.36 (t, 1=20.5 Hz), 112.88 (two C), 111.22 (dd, 
11=19.4 Hz, 12=7.2 Hz, two C), 40.10 (two C), 34.73, 24.75. 
MS: m/z (%) 261 (40), 134 (100), 118 (27), 91 (22). Anal. 
CalcdforC16H17F2N: C, 73.54; H, 6.56. Found: C, 73.53; H, (s, 6H). 
13C NMR (acetone-d6): o156.09 (ddd, 11=243.9 Hz, 
12=5.3 Hz, 13=2.4 Hz), 151.31, 147.94 (m, two C), 137.17 (t, 
1=8.4 Hz), 128.23 (two C), 124.89, 117.43 (dd, 11=17.1 Hz, 
12=12.1 Hz), 114.02 (dd, 11=19.4 Hz, 12 =10.2 Hz), 112.33 
(two C), 111.21 (ddd, 11=25.5 Hz, 12=7.6 Hz, 13=3.8 Hz), 
108.99, 39.59 (two C). MS: m/z (%) 277 (100), 276 (83), 261 
(24), 214 (16), 213 (12). Anal. Calcd for C16H14F3N: C, 60 
69.30; H, 5.09. Found: C, 69.50; H, 4.97. 
55 6.49. 
Example 2 
Synthesis of Metabolites of Halogenated Stilbene 
Analogs 
Synthesis of (E)-N,N-Dimethyl-4-(2,4,6-trifluo-
rostyryl)aniline (4w) 
Procedure B. Yield 63%. Light yellow crystals from hex-
ane. mp 127-128° C. 1H NMR (acetone-d6): o 7.45 (d, 2H, 
General Procedure: 
To a stirred solution of 4 (0.7 mmol) in CHC13 (3 mL) was 
added 70% m-CPBA (0.7 mmol, 1 equiv), portionwise at oo 
65 C. The resulting mixture was stirred at room temperature for 
5 h. The mixture was diluted with CH2Cl2 (15 mL), washed 
with saturated NaHC03 solution and water, dried over anhy-
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drous MgS04 and concentrated. The product was purified by 
chromatography as noted for individual amine N-oxides 
listed below. 
34 
Synthesis of (E)-4-(2-chloro-6-fluorostyryl)-N-me-
thylaniline ( 4dd) 
The procedure used to prepare 4 cc was repeated using 1 g 
Synthesis of (E)-4-(2,6-difluorostyryl)-N,N-dimethy-
laniline oxide ( 4z) 
Yield 72%. Rf=0.31 (1:5 CH30H-CH2Cl2).mp 100-103° 
C. 1H NMR (DMSO-d6 ): o8.11 (d, 2H, 1=8.4 Hz), 7.72 (d, 
2H, 1=8.8 Hz), 7.43-7.35 (m, 2H), 7.21-7.15 (m, 3H), 3.40 (s, 
6H). 13C NMR (DMSO-d6 ): o 160.85 (dd, 11=249.0 Hz, 
12=7.6 Hz, two C), 156.35, 137.30, 134.60 (t, 1=7.6 Hz), 
130.13 (t, 1=10.7 Hz), 127.42 (two C), 121.67 (two C), 
116.40, 114.44 (t, 1=15.2 Hz), 112.76 (dd, 1 1=19.0 Hz, 12=6.1 
Hz, two C), 63.92 (two C). HRMS (EI) Calcd for 
C16H15F2 NO: 275.1121. Found: 275.1120. 
5 (3.63 mmol) of 4x and 764 mg (7.26 mmol, 2 equiv) of 
cyanogen bromide to afford a product that was purified by 
chromatography using 1:5 EtOAc-hexane to afford 400 mg 
(42%) of 4dd as a yellow solid: mp 43-45° C. 1H NMR 
(DMSO-d6): 67.37-7.31 (m, 3H), 7.27-7.21 (m, 2H), 7.18 (d, 
10 lH, 1=16.4 Hz), 6.88 (d, lH, 1=16.4 Hz), 6.56 (d, 2H, 1=8.8 
Hz), 6.04 (q, lH, 1=5.2 Hz), 2.71 (d, 3H, 1=5.2 Hz). 13CNMR 
(DMSO-d6): o 160.75 (d, 1=248.0 Hz), 150.98, 137.24 (d, 
1=12.2 Hz), 133.30 (d, 1=6.1 Hz), 128.49 (two C), 128.33 (d, 
1=9.9 Hz), 126.28 (d, 1=3.1 Hz), 124.73 (d, 1=14.5 Hz), 
Synthesis of (E)-4-(2-chloro-6-fluorostyryl)-N,N-
dimethylaniline oxide (4aa) 
15 124.40, 115.54 (d, 1=22.9 Hz), 113.12 (d, 1=2.2 Hz), 112.11 
(two C), 29.94. MS: m/z (%) 261 (100), 227 (15), 213 (25). 
Anal. Calcd for C15H13Cl FN: C, 68.84; H, 5.01. Found: C, 
68.67; H, 5.05. 
20 
Yield 54%. Yellow solid. Rf=0.34 (1 :5 CH3 0H---CH2 Cl2 ). 
mp 82-84° C. 1HNMR(acetone-d6 ): o8.21 (d, 2H, 1=8.8 Hz), 
7.73 (d, 2H, 1=8.8 Hz), 7.43 (d, lH, 1=16.4 Hz), 7.38-7.32 (m, 
3H), 7.26-7.21 (m, 1H),3.50(s, 6H). 13CNMR(acetone-d6): 25 
o161.29 (d, 1=249.8 Hz), 156.41, 137.41, 135.20 (d, 1=12.1 
Hz), 134.40 (d, 1=5.3 Hz), 129.41 (d, 1=10.6 Hz), 126.98 (two 
C), 126.06 (d, 1=3.0 Hz), 123.93 (d, 1=14.4 Hz), 121.41 (two 
C), 120.31 (d, 1=1.5 Hz), 115.19 (d, 1=23.6 Hz), 63.27 (two 
C). HRMS (EI) Calcd for C16H15ClFNO: 291.0826. Found: 30 
291.0828. 
Synthesis of (E)-4-(2,6-dichlorostyryl)-N,N-dim-
ethylaniline oxide (4bb) 
Synthesis of (E and Z)-4-(2,6-dichlorostyryl)-N-
methylaniline ( 4ee) 
The procedure used to prepare 4 cc was repeated using 1 g 
(3.42 mmol) of 4y and 720 mg (6.84 mmol, 2 equiv) of 
cyanogen bromide to afford a product that was purified by 
chromatography (multiple times and each time using two 
developments) using 1:5 EtOAc-hexane to afford 390 mg 
(41%) of 4ee as a 9:1 E:Z-mixture of isomers that was a 
yellow oil. 1H NMR (DMSO-d6 ): o 7.49 (d, 2H, 1=8.4 Hz), 
7.35 (d, 2H, 1=8.4 Hz), 7.24 (t, lH, 1=8.0 Hz), 6.99 (d, lH, 
1=16.4 Hz), 6.82 (d, lH, 1=16.4 Hz), 6.55 (d, 2H, 1=8.4 Hz), 
6.01 (q, lH, 1=5.2 Hz), 2.70 (d, 3H, 1=502 H2 ). 
13C NMR 
(DMSO-d6): o150.45, 137.40, 134.69, 133.36, 128.86 (two 
C), 128.28, 127.97 (two C), 123.47, 116.09 (two C), 111.57 
35 (two C), 29.50. HRMS (EI) CalcdforC15H13Cl2N: 277.0425. 
Yield 80%. Rf=0.19 (1:10 CH3 0H---CH2Cl2 ). mp 80-82° 
C. 1H NMR (DMSO-d6 ): o 8.13 (d, 2H, 1=9.2 Hz), 7.71 (d, 
2H, 1=9.2 Hz), 7.55 (d, 2H, 1=8.4 Hz), 7.34 (t, lH, 1=8.0 Hz), 
7.22 (d, lH, 1=16.8 Hz), 7.11 (d, lH, 1=16.8 Hz), 3.41 (s, 6H). 
13C NMR (DMSO-d6 ): o 156.31, 136.52, 136.12, 134.51, 40 
134.11, 129.97, 129.34 (two C), 127.24 (two C), 123.85 (two 
C), 121.49 (two C), 63.78 (two C). HRMS (EI) Calcd for 
C16H15Cl2NO: 307.0531. Found: 307.0530. 
Found: 277.0425. 
Synthesis of (E)-4-(2,6-difluorostyryl)-N,N,N-trim-
ethylbenzenaminium iodide ( 4ff) 
To a solution of 200 mg (0.77 mmol) of 4r in acetone (2 
mL) was added CH3 I 328 mg (2.31 mmol, 3 equiv). The 
resulting mixture was refluxed for 8 h. The precipitate formed 
was collected by filtration, washed with ethyl ester, and the 
Synthesis of (E)-4-(2,6-Difluorostyryl)-N-methyla-
niline ( 4 cc) 
45 residual solvent was removed in vacuo to afford 200 mg 
(64%) of 4ff as a white solid: mp 198-199° C. 1H NMR 
(DMSO-d6): o7.98 (d, 2H, 1=8.8 Hz), 7.91 (d, 2H, 1=9.2 Hz), 
7.47-7.38 (m, 2H), 7.29 (d, lH, 1=16.8 Hz), 7.23-7.17 (m, A solution of 1 g (3.86 mmol) of 4r and 820 mg (7.72 
mmol, 2 equiv) of cyanogen bromide in 15 mL of acetone was 
refluxed for 16 h. The mixture was cooled and concentrated 50 
under a stream of argon. The residue was triturated with ether, 
and the combined ethereal extracts were combined and con-
centrated. The product was refluxed with 25 mL of concen-
trated HCl for 3 h. The mixture was neutralized with 2M 
NaOH solution, extracted with ether, dried over anhydrous 55 
MgSO 4 , and concentrated. The product was purified by chro-
matography using 1:5 EtOAc-hexane to afford 320 mg (34%) 
of 4 cc as a yellow solid: mp 51-52° C. 1 H NMR (DMSO-d6): 
o 7.32 (d, 2H, 1=8.8 Hz), 7.29-7.21 (m, 2H), 7.14-7.06 (m, 
2H), 6.79 (d, lH, 1=16.4 Hz), 6.55 (d, 2H, 1=8.8 Hz), 6.02 (q, 60 
lH, 1=5.2Hz), 2.70 (d, 3H, 1=5.2Hz). 13CNMR(DMSO-d6): 
o160.36 (dd, 11 =246.8 Hz, 12=8.0 Hz, two C), 150.88, 136.35 
(t, 1=7.5 Hz), 128.42 (two C), 127.96 (d, 1=10.7 Hz), 124.53, 
115.32 (t, 1=15.5 Hz), 112.33 (dd, 11 =19.1 Hz, 12 =6.8 Hz, two 
C), 112.09 (two C), 108.86, 29.93. MS: m/z (%) 246 (30), 245 65 
(100), 244 (15). Anal. Calcd for C15H13F2N: C, 73.45; H, 
5.34. Found: C, 73.31; H, 5.26. 
2H), 3.62 (s, 9H). 13C NMR (DMSO-d6 ): o 160.30 (dd, 
11=249.1 Hz, 12=7.4 Hz, two C), 146.72, 138.44, 133.04 (t, 
1=7.8 Hz), 130.00 (t, 1=10.8 Hz), 128.05 (two C), 121.03 (two 
C), 117.44, 113.58 (t, 1=15.5 Hz), 112.23 (dd, 11=19.2 Hz, 
12=5.7 Hz, two C), 56.45 (three C). Anal. Calcd for 
C17H18F21 N: C, 50.89; H, 4.52. Found: C, 51.10; H, 4.49. 
Example 3 
Synthesis ofBiotinylatedAnalogs of Halogenated 
Stilbenes 
In this example, several biologically active biotin-labeled 
halogenated stilbene analogs, in particular fluorinated N,N-
dialkylaminostilbenes (FIDAS or FIDAS agents), where pre-
pared. As shown in FIG. 4, several Biotin-FIDAS compounds 
with variable spacers between the FIDAS agent and the biotin 
were prepared. It was established, through the synthesis of 
other amides lacking the biotin heterocycle or possessing 
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7.37 (d, lH, 1=16.8 Hz), 7.23-7.17 (m, 2H). 13C NMR 
(DMSO-d6): o 160.79 (dd, 11=249.4 Hz, 12=7.3 Hz, two C), 
147.27, 143.81, 133.35 (t, 1=7.9 Hz), 130.82 (t, 1=10.7 Hz), 
128.21 (two C), 124.46 (two C), 119.70 (t, 1=1.6 Hz), 113.79 
biotin alone, that activity resides in the stilbene and not in the 
biotin portion of these molecules. The optimal spacer length 
between the two termini was determined, and the binding and 
eluting conditions for Biotin-FIDAS and streptavidin beads 
were established. 5 (t, 1=15.1 Hz), 112.65 (dd, 11=19.5 Hz, 12=5.9 Hz, two C). 
Synthesis of (E)-4-(2,6-Difluorostyryl)-N,N-dim-
ethyl-3-nitroaniline (6) 
To a solution of 1.63 g (6.18 mmol, 1.2 equiv) of diethyl 10 
2,6-difluorobenzylphosphonate in 15 mL of anhydrous DMF 
at oo C. was added 310 mg (7.72 mmol, 1.5 equiv) of 60% 
NaH. The mixture was stirred for 30 min, and a solution ofl.O 
g (5.15 mmol) of 4-(dimethylamino)-3-nitrobenzaldehyde in 
8 mL of anhydrous DMF was added over a 10 min period. The 15 
mixture was stirred for 2 hat oo C. and poured into cold water. 
The precipitate was collected by filtration and recrystallized 
from acetonitrile to afford 1.1 g (70%) of 6 as red crystals: mp 
152-153° C. 1 H NMR (acetone-d6): o 7.81 (d, 1H, 1=8.8 Hz), 
7.68 (d, lH, 1=16.4 Hz), 7.38-7.30 (m, lH), 7.17 (d, lH, 1=3.2 20 
Hz), 7.10-7.03 (m, 3H), 7.01 (d, lH, 1=16.8 Hz), 3.1 (s, 6H). 
13C NMR (acetone-d6): o 160.76 (dd, 11=248.3 Hz, 12=7.5 
Hz, two C), 150.56, 150.03, 129.66 (t, 1=8.7 Hz), 128.73 (t, 
1=10.7 Hz), 128.08, 118.20, 116.16, 114.92 (t, 1=1.6 Hz), 
114.52 (t, 1=15.1 Hz), 111.74 (dd, 11 =19.7 Hz, 12=6.5 Hz, two 25 
C), 106.01, 39.31 (two C). HRMS (EI) Calcd for 
C16H14F2 N20 2 : 304.1023. Found: 304.1016. 
MS: m/z (%) 261 (61), 231 (67), 214 (45), 194 (34), 183 
(100).Anal. CalcdforC14H9 F2 NO: C, 64.37; H, 3.47. Found: 
C, 64.56; H, 3.42. 
Synthesis of (E)-4-(2,6-Difluorostyryl)aniline (9) 
The procedure described for the preparation of 7 was 
repeated using 300 mg (1.15 mmol) of 8 in 20 mL of glacial 
HOAc and 1.85 g (9.76 mmol, 8.5 equiv) ofSnC12 in 3 mL of 
cone HCl to afford, after stirring ca. 12 h at 25° C. and 
quenching with water, a precipitate. The precipitate was col-
lected by filtration, washed with 5 mL of glacial acetic acid 
and suspended in 80 mL of water. The aqueous suspension 
was adjusted to pH 9-10 with NaOH and was extracted with 
Et2 0. The combined ethereal extracts were washed with 
water, dried over anhydrous MgS04 , and concentrated. The 
product was recrystallized from hexane to afford 220 mg 
(83%) of 9 as colorless crystals: mp 74-75° C. 1H NMR 
(DMSO-d6): o 7.28 (d, 2H, 1=8.8 Hz), 7.27-7.22 (m, lH), 
7.21 (d, lH, 1=16.8 Hz), 7.13-7.06 (m, 2H), 6.77 (d, lH, 
Synthesis of (E)-4-(2,6-Difluorostyryl)-W ,W -dim-
ethylbenzene-1,3-diamine (7) 
1=16.8 Hz), 6.57 (d, 2H, 1=8.8 Hz), 5.43 (s, 2H). 13C NMR 
(DMSO-d6): o 160.35 (dd, 11=246.8 Hz, 12=8.0 Hz, two C), 
150.06, 136.41 (t, 1=7.9 Hz), 128.42 (two C), 127.99 (t, 
1=10.3 Hz), 124.68, 115.31 (t, 1=15.1 Hz), 114.29 (two C), 
112.33 (dd, 11=19.1 Hz, 12=6.3 Hz, two C), 108.84. MS: m/z 
(%) 232 (18), 231 (100), 183 (13). Anal. Calcd for 
3° C14H11F2N: C, 72.72; H, 4.79. Found: C, 72.77; H, 4.83. 
A solution of5 g (26.4 mmol, 8.5 equiv) ofSnC12 in 7 mL 
of cone HCl was added dropwise to a solution of0.95 g (3.1 
mmol) of 6 in 100 mL of glacial acetic acid. The mixture was 
stirred for ca. 12 hat 25° C. A precipitate was collected by 35 
filtration, washed with 5 mL of glacial acetic acid, and sus-
pended in 200 mL of water. The aqueous suspension was 
adjusted to pH 9-1° with NaOH and was extracted with Et2 0. 
The combined ethereal extracts were washed with water, 
dried over anhydrous MgS04 and concentrated. The residue 40 
was recrystallized from ethanol to afford 590 mg (69%) of7 
as yellow crystals: mp 97-98° C. 1 H NMR (DMSO-d6 ): o 7.41 
(d, lH, 1=16.4 Hz), 7.27 (d, lH, 1=8.8 Hz), 7.24-7.18 (m, lH), 
7.12-7.05 (m, 2H), 6.61 (d, lH, 1=16.4 Hz), 6.10 (dd, lH, 
11 =8.8 Hz, 12=2.4 Hz), 6.03 ( d, lH, 1=2.8 Hz), 5.05 (br.s, 2H), 45 
2.87 (s, 6H). 13C NMR (DMSO-d6): o 160.25 (dd, 11=246.0 
Hz, 12=7.9 Hz, two C), 151.95, 147.98, 132.39 (t, 1=7.1 Hz), 
127.45 (t, 1=11.1 Hz), 127.06, 116.11 (t, 1=15.1 Hz), 112.20 
(dd, 11=18.7 Hz, 12=6.8 Hz, two C), 111.39, 108.21, 103.52, 
99.07, 40.28 (two C). MS: m/z (%) 275 (21), 274 (100), 273 50 
(33), 257 (15), 211 (16). Anal. Calcd for C16H16F2 N2 : C, 
70.06; H, 5.88. Found: C, 70.18; H, 5.94. 
Synthesis of (E)-N-(2-(2,6-Difluorostyryl)-5-(dim-
ethylamino )phenyl)-5-(2-oxohexahydro-1 H -thieno 
[3,4-d]imidazol-4-yl)pentanamide (1 0) 
To 200 mg (0.82 mmol) of biotin was added 8 mL (0.11 
mol) of SOC12 . The mixture was stirred for 1 hat 25° C. The 
mixture was concentrated and co-evaporated with benzene 
(two 15 mL portions) to give the acid chloride. To a solution 
of186 mg (0.68 mmol) of7 and 83 mg (0.82 mmol, 1.2 equiv) 
of Et3N in 5 mL of anhydrous THF was added the acid 
chloride in 8 mL of anhydrous THF dropwise. The mixture 
was stirred for 2 hat 25° C., poured into water and extracted 
with CH2Cl2 . The combined organic phases were dried over 
anhydrous MgSO 4 and evaporated to give a product that was 
purified by chromatography using 1:10 CH30H-CH2 Cl2 to 
afford 200 mg (59%) of 10 as a yellow solid: mp 183-184° C. 
1H NMR (DMSO-d6 ): o 9.51 (s, lH), 7.61 (d, lH, 1=8.8 Hz), 
7.40 (d, lH, 1=16.4 Hz), 7.32-7.24 (m, lH), 7.15-7.09 (m, 
2H), 6.80 (d, lH, 1=16.8 Hz), 6.67-6.61 (m, 2H), 6.45 (s, lH), 
6.36 (s, lH), 4.31-4.28 (m, lH), 4.15-4.11 (m, lH), 3.12-3.07 
(m, lH), 2.93 (s, 6H), 2.80 (dd, lH, 11=12.4 Hz, 12=5.2 Hz), 
2.57 (d, lH, 1=12.4 Hz), 2.31 (t, 2H, 1=7.2 Hz), 1.69-1.35 (m, 
6H). 13C NMR (DMSO-d6): o 171.90, 163.14, 160.40 (dd, Synthesis of (E)-1 ,3-Difluoro-2-( 4-nitrostyryl)ben-
zene (8) 
To a solution of 956 mg (2 mmol) of ( 4-nitrobenzyl)triph-
enylphosphonium bromide and 284 mg (2 mmol) of 2,6-
difluorobenzaldehyde in 20 mL ofCH2 Cl2 was added 5 mL of 
0.48 M NaOH solution (2.4 mmol, 1.2 equiv) dropwise over 
55 11=247.6 Hz, 12=7.9 Hz, two C), 151.03, 137.35, 132.05 (t, 
1=8.0 Hz), 128.27 (t, 1=11.0 Hz), 126.36, 120.44, 115.40 (t, 
1=15.0 Hz), 112.36 (dd, 11=19.1 Hz, 12=6.4 Hz, two C), 
110.93, 110.65, 110.20, 61.47, 59.64, 55.86, 40.40 (two C), 
40.31, 36.11, 28.70, 28.55, 25.84. HRMS (EI) Calcd for 
60 C26H30F2N4 0 2 S: 500.2057. Found: 500.2047. 
a 10 min period. The red solution was heated at 50° C. for 1 h. 
The organic layer was separated, washed with a saturated 
aqueous NaHS03 solution and water, and dried over anhy-
drous MgS04 . The residue was recrystallized from ethanol to 
afford 360 mg (69%) of 8 as light yellow crystals: mp 136- 65 
137° C. 1H NMR (DMSO-d6): o 8.23 (d, 2H, 1=8.8 Hz), 7.93 
(d, 2H, 1=8.8 Hz), 7.50 (d, lH, 1=16.8 Hz), 7.46-7.40 (m, lH), 
Synthesis of (E)-N-(4-(2,6-Difluorostyryl)phenyl)-5-
(2-oxohexahydro-1 H-thieno [3,4-d]imidazol-4-yl) 
pentanamide (11) 
To a suspensionoflOOmg (0.41 mmol1 equiv) ofbiotinin 
3 mL of anhydrous DMF was added 66 mg (0.49 mmol, 1.2 
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equiv) of 1-hydroxybenzotriazole hydrate, 94 mg (0.49 
mmol, 1.2 equiv) of N-(3-dimethylaminopropyl)-N'-ethyl-
carbodiimide hydrochloride, and 79 mg (0.78 mmol, 1.9 
equiv) ofEt3 N. The mixture was stirred for 10min, and95 mg 
(0.41 mmol) of9 was added. The mixture was stirred for 24 h 5 
at 25° C. and poured into water. The precipitate was collected 
by filtration and chromatographed using 1:1 EtOAc-MeOH 
to give 120 mg (66%) of11 as white crystals: mp 278-280° C. 
1HNMR(DMSO-d6): o9.99 (s, lH), 7.64 (d, 2H, 1=8.8 Hz), 
7.56 (d, 2H, 1=8.8 Hz), 7.37-7.29 (m, 2H), 7.19-7.12 (m, 2H), 10 
7.02 (d, lH, 1=16.4 Hz), 6.44 (s, lH), 6.36 (s, lH), 4.33-4.29 
(m, lH), 4.16-4.13 (m, lH), 3.15-3.10 (m, lH), 2.83 (dd, lH, 
1 1=12.8 Hz, 12 =4.8 Hz), 2.58 (d, lH, 1=12.0 Hz), 2.33 (t, 2H, 
1=7.2 Hz), 1.70-1.33 (m, 6H). 13C NMR (DMSO-d6): o 
171.70, 163.13, 160.53 (dd, 11 =247.8 Hz, 12=7.7 Hz, two C), 15 
140.09, 135.28 (t, 1=7.9 Hz), 131.77, 129.18 (t, 1=10.7 Hz), 
127.69 (two C), 119.54 (two C), 114.61 (t, 1=15.5 Hz), 
113.25, 112.45 (dd, 11=19.1 Hz, 12=6.3 Hz, two C), 61.48, 
59.63, 55.82, 40.28, 36.70, 28.67, 28.53, 25.50. HRMS (EI) 
Calcd for C24H25F2 N30 2 S: 457.1636. Found: 457.1650. 20 
Anal. Calcd for C24H25F2 N30 2 S: C, 63.00; H, 5.51. Found: 
C, 62.82; H, 5.47. 
38 
4.34-4.29 (m, lH), 3.97 (s, 2H), 3.59-3.45 (m, 8H), 4.42-3.29 
(m, 4H), 3.23-3.17 (m, lH), 3.13 (s, 3H), 2.92 (dd, lH, 
11=12.4 Hz, 12=4.8 Hz), 2.69 (d, lH, 1=12.4 Hz), 2.18 (t, 2H, 
1=7.2 Hz) 1.81-1.39 (m, 6H). It was noted that the MALDI-
TOFMS Calcd for C33H44F2N5 0 5 S [MH+]: 660.3030. 
Found 660.3040. 
Example 4 
Natural Stilbene Analogues Resveratrol and 
Pterostilbene Inhibit Wnt Signaling 
Materials and Methods: 
The following materials and methods have been used to 
generate the results in this and other examples in the applica-
tion. 
Cell Culture and Transfection. 
HEK293T, HCT116 and SW 480 cells were grown in 
DMEM medium (Mediatech) supplemented with 10% fetal 
bovine serum and 1% penicillin/streptomycin. LS 17 4 T cells 
were grown in RPMI medium (Mediatech) supplemented 
with 5% fetal bovine serum and 1% penicillin/streptomycin. 
HEK293T cells were transiently transfected using the cal-
cium phosphate method as described in Zhang, W. eta!., Mol Synthesis of (E)-N-( 4-(2,6-Difluorostyryl)phenyl)-
N -methyl-5-(2-oxohexahydro-1 H -thieno[3,4-d]imi-
dazol-4-yl)pentanamide (12) 
25 Cell Biol2006, 26, 2055-2064 (incorporated herein by refer-
ence). 
The procedure used to prepare 10 was repeated using 167 
mg (0.68 mmol) of 4 cc and 200 mg (0.82 mmol, 1.2 equiv) of 
biotin to afford a product that was purified by chromatogra- 30 
phy using 1:10 CH30H-CH2Cl2 to afford 130 mg (41%) of 
12 as a colorless solid: mp 91-93° C. 1HNMR (DMSO-d6): o 
7.71 (d, 2H, 1=8.0 Hz), 7.41-7.36 (m, 2H), 7.33 (d, 2H, 1=8.4 
Hz), 7.21-7.14 (m, 3H), 6.38 (s, lH), 6.33 (s, lH), 4.30-4.26 
(m, lH), 4.09-4.06 (m, lH), 3.17 (s, 3H), 3.05-3.00 (m, lH), 35 
2.80 (dd, lH, 11=12.2 Hz, 12=5.2 Hz), 2.56 (d, lH, 1=12.4 
Hz), 2.09 (br.s, 2H), 1.58-1.18 (m, 6H). 13C NMR (DMSO-
d6): o171.96, 163.13, 160.61 (dd, 11=248.0 Hz, 12=7.6 Hz, 
two C), 144.40, 134.71 (t, 1=7.9 Hz), 129.80 (t, 1=11.1 Hz), 
128.27 (two C), 128.07, 128.01, 115.70 (two C), 114.35 (t, 40 
1=15.1 Hz), 112.54 (dd, 11=19.1 Hz, 12=6.4 Hz, two C), 
61.42, 59.62, 55.75, 40.27, 37.20, 33.64, 28.54, 28.43, 25.32. 
MALDI-TOFMS Calcd for C25H28F2 N30 2 S [MH+]: 
472.1870. Found 472.1872. 
Western Blot. 
Western blots were performed using the following antibod-
ies: ~-catenin (Sigma, C2206), c-Myc (Epitomics, 1472-1), 
Axin2 (Cell Signaling, 2151), ~-Actin (Sigma, A1978), 
TCF 4 (Epitomics, 2114-1) and pygopus2 (Santa Cruz, 
sc-74878), Cyclin D1 (Cell signaling, 2926). 
RT-PCR. 
LS174 cells were treated with DMSO or Wnt inhibitors. 
After 36 h, RNA was isolated using the RNeasy kit (Qiagen). 
RT-PCR was performed as described in Zhang et tal., Mol 
Cell Biol 2006, 26, 2055-2064. The following primers were 
used: ~-actin: 5'-CAACCGCGAGAAGATGAC-3' (SEQ ID 
N0:01), 5'-AGGAAGGCTGGAAGAGTG-3' (SEQ ID 
N0:02); surivivin: 5'-CATTCGTCCGGTTGCGCTTTCC-3' 
(SEQ ID N0:03), 5'-GCGCACTTTCTCCGCAGTTTCC-3' 
(SEQ ID N0:04); c-Myc: 5'-TGGGCTGTGAGGAG-
GTTTG-3' (SEQ ID N0:05), 5'-TATGTGGAGCGGCT-
TCTCG-3' (SEQ ID N0:06); Axin2: 5'-CACCACCACCAC-
45 CACCATTC-3' (SEQ ID N0:07), 
Synthesis of N -(2-( 4-(2,6-Difluorostyryl)phenyl)-4-
oxo-8, 11-dioxa-2,5-diazamidecan-13-yl)-5-(2-oxo-
hexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentana-
mide (13) 
To a solution of34 mg (0.14 mmol, 1.5 equiv) of 4 cc in 1 
mL of absolute ethanol was added 50 mg (0.092 mmol) of 
( + )-biotinyl-iodoacetamidyl-3,6-dioxaoctanediamine and 20 
mg (0.14mmol, 1.5 equiv) ofanhydrousK2 COy The mixture 
was refluxed for 12 h, filtered, and concentrated. The product 
was chromatographed using 1:10 CH30H-CH2Cl2 to afford 
16 mg (26%) of 13 as a clear glass that resisted crystallization. 
The initial product isolated was the pure (E)-isomer but dur-
ing concentration, even at low temperature, rapidly equili-
brated to a mixture of (E/Z)-isomers. The ratio of isomers 
varied with solvent ranging from ca. 10:90 in acetone-d6 to 
60:40 in DMSO-d6. This isomerization necessarily compli-
cated the NMR spectra, and the data reported below is for the 
principal (E)-isomer: 1H NMR (acetone-d6): 7.48 (d, 2H, 
1=8.8 Hz), 7.42-7.35 (m, 2H), 7.30-7.22 (m, lH), 7.13 (br.s, 
lH), 7.05-7.00 (m, 2H), 6.95 (d, lH, 1=16.8 Hz), 6.75 (d, 2H, 
1=9.2 Hz), 5.87 (s, lH), 5.64 (s, lH), 4.51-4.46 (m, lH), 
5'-GCATCCACTGCCAGACATCC-3' (SEQ ID N0:08); 
TCF4: 5'-CACCACATCATACGCTACAC-3' (SEQ ID 
N0:09), 5'-CGACCTTTGCTCTCATTTCC-3' (SEQ ID 
NO: 1 0); pygopus2: 5'-GGCCGGTCTGCAAATGAAG-3' 
so (SEQ ID NO: 11 ), 5'-TCCACCTCCAGTGCTGTAG-3' (SEQ 
ID N0:12); Lgr5: 5'-CCTGCTTGACTTTGAGGAAGAC-3' 
(SEQ ID N0:13), 5'-ATGTTCACTGCTGCGATGAC-3' 
(SEQ ID N0:14); CD44: 5'-CAGAATGGCTGAT-
CATCTTG-3' (SEQ ID NO: 15), 5'-CAAATGCACCATTTC-
ss CTGAG-3' (SEQ ID N0:16); Ki67: 5'-ACAGAGTGCT-
CAACAACTTC-3' (SEQ ID NO: 17), 
5'-GCTTGCAGAGCATTTATCAG-3' (SEQ ID NO: 18). 
Luciferase and Cell Proliferation Assay. 
HEK293T cells were transiently transfected in a 12-well 
60 plate with 0.2 flg of the Super8xTOPFlash reporter and 0.05 
flg of Renilla luciferase reporter. Culture medium was 
changed after 12 h. After 6 h, cells were treated with DMSO 
or Wnt inhibitors for 12 h, and then treated with 25 mM LiCl 
or Wnt conditioned medium. After 12 h, cells were harvested 
65 and luciferase activity measured by Dual-luciferase Reporter 
Assay System (Promega, Madison Wis.). All conditions were 
done in triplicate and each experiment was carried out at least 
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two times. For cell proliferation assay, CRC cells were treated 
with DMSO or inhibitors for 2 d and 4 d. The cell numbers 
and viability were analyzed by Vi-Cell Cell Viability Ana-
lyzer. 
40 
Many stilbene derivatives also exhibit anti-cancer activity. 
To determine the structure/activity relationship of these com-
pounds, several resveratrol analogs were tested. It was found 
that pterostilbene inhibits Wnt signaling. To determine the 
Tumor Xenograft in Nude Mice. 5 effects of resveratrol and pterostilbene on cell growth, LS 17 4 
CRC cells were treated with resveratrol and pterostilbene for 
2 d and 4 d. Both compounds inhibited cell proliferation. 
Similar results were observed with other CRC lines Pteros-
LS174 or HT29 colon cancer cells (2x106) were injected 
subcutaneously into both flanks of 6-8 week C57BL/6J athy-
mic nude mice as described in Zhang et a!., Mol Cell Biol 
2006, 26, 2055-2064. Compound 4r or 4dd was dissolved in 
corn oil or PEG400. The mice were treated with 20 mg/kg/ day 10 
of 4r by ip injection or gavage (50 fll/mouse). Control mice 
were treated with same volume of corn oil or PEG400. The 
body weight and tumor growth were analyzed twice weekly 
for one month. Tumor size was measured using digital caliper. 
15 
The tumor volume was calculated by the formula: V= 1/2LW2 
(mm3). 
Immunofluorescence. 
tilbene was more active than resveratrol in these assays, sug-
gesting that an assay involving Western blots to measure Wnt 
target protein level was effective to identifY other resveratrol 
analogs for Wnt inhibition and CRC repression. 
Example 5 
Halogenated Stilbene Analogs are Potent Wnt 
Inhibitors 
Cells grown on cover glass were fixed by 4% paraformal-
dehyde for 20 min at room temperature. The cells were per- 20 
meabilized with PBS containing 0.3% (w/v) Triton X-100 
and blocked by 5% normal goat serum in PBS for 30 min 
Anti-~-catenin antibody (1:300, Sigma, St. Louis, Mo.) was 
diluted in blocking solution and incubated with cells over-
night. The cells were washed 3 times with PBS and further 25 
incubated with Alexa-488-labeled anti-rabbit IgG (1:500) 
diluted in PBS for 40 min. The cover glasses were washed, 
mounted on glass slides, viewed and photographed with an 
Olympus FW1000 confocal microscope. Cells grown on 
cover glass were treated with fluorescent compounds for 2 h, 30 
6 h, 12 hand24 hrespectively. Treated cells were fixed by 4% 
paraformaldehyde for 20 min at room temperature. Then cells 
were washed 3 times with PBS and mounted on glass slides, 
viewed under the fluorescence of 405 urn-wavelength and 
photographed with an Olympus FW1000 confocal micro- 35 
A panel of stilbene analogs was designed and synthesized 
(FIGS. 2, 3, SA and 6A). Various monosubstituted hydroxyl, 
alkoxy, amino and N,N -dialkylaminostilbenes were analyzed 
using the Western blot assay (FIG. SB, SC), and of these 
substituents, (E)-4-styryl-N,N-dimethylaniline ( 4d) at 30 f.LM 
with an N,N-dimethylamino substituent strongly repressed 
Wnt target genes, Axin2 and c-Myc, in CRC cells (FIG. SC). 
However, the solubility of 4d was poor and it was not effective 
below 10 f.LM concentrations (data not shown). To improve its 
solubility and activity, compound 4d was modified with 
2'-fluoro 4e, 3'-fluoro 4f and 4'-fluoro 4g substituents (FIG. 
SD). Both compounds 4e and 4fhad good activity at 10 f.LM, 
(E)-4-(2-fluorostyryl)-N,N-dimethylaniline. Compound ( 4e) 
was best among all of the monofluoro-substituted com-
pounds. Modifications of the N,N-dimethylamino group 
within compound 4e were also analyzed, and it was found that 
the N,N-diethylamino group in (E)-4-(2-fluorostyryl)-N,N-
diethylaniline ( 4h) is also active at 10 f.LM, but not as potent as scope. 
To identifY Wnt pathway inhibitors for CRC prevention 
and treatment, a number of anti-cancer agents from plants 
were screened using the TopFlash reporter assay. The Top-
Flash reporter was transfected into HEK293T cells, and the 
cells were treated with Wnt3A-conditioned medium in order 
to activate the luciferase reporter. Resveratrol (100 f.LM) sig-
nificantly inhibited Wnt-induced luciferase activity. To deter-
mine ifresveratrol regulates ~-catenin degradation, the cells 
were treated with 25 mM LiCl, which inhibits GSK-3 and 
stabilizes ~-catenin. In this assay, LiCl activated the reporter 
more strongly than W nt3A conditioned medium. Resveratrol 
strongly inhibited LiCl-induced Wnt signaling, suggesting 
that resveratrol inhibits W nt signaling by regulating ~ -catenin 
activity, but not its degradation. Emodin is an anti-cancer 
agent from plants; it exists in many unpurified resveratrol 
products. Emodin had no effect on Wnt signaling. See Zhang 
eta!., J. ofMed. Chern. 54, 1288-1297 (2011). 
To confirm these results, ~-catenin target genes were ana-
lyzed in LS174 CRC cells by Western blot and RT-PCR. The 
protein levels of c-Myc and Cyclin D1, which are ~-catenin 
targets, are reduced by resveratrol but not its isomer, cis- or 
(Z)-resveratrol. Cyclin B1 levels were decreased, whereas 
p21 WAFliCIPl levels increased, consistent with the fact that 
p21 WAFliCIPl expression is repressed by c-Myc. ~-catenin 
levels were not affected by resveratrol. Next, the mRNA 
levels of~-catenin target genes were analyzed using RT-PCR. 
Expression of survivin, Lgr5, CD44, and c-Myc were 
decreased in resveratrol-treated cells. The cell proliferation 
marker, Ki67, also decreased. These results confirmed that 
resveratrol inhibits endogenous Wnt target genes in CRC 
cells. 
compound 4e and the N,N-diphenylamino group in com-
pound 4i was inactive (FIG. SE). These analogs had no effect 
on ~-catenin levels, further indicating that they affect ~-cate-
40 nin activity, but not its stability. The effects of compound 4e, 
resveratrol, and pterostilbene on CRC cell growth were com-
pared and it was found that 4e is a significantly better inhibitor 
in the cell proliferation assay (FIG. SF). 
Based on the improved activity seen in compound 4e rela-
45 tive to compound 4d, dihalogenated N,N-dimethylaminostil-
benes in which at least one of the fluorine substituents is in the 
2'- or 3'-position were synthesized (FIG. 6A). The com-
pounds with a 2'-flu oro and another fluoro ortho or meta to the 
double bond (compounds 4m, 4o and 4r) are more active than 
50 compound 4e (FIG. 6B). The (E)-4-(2,6-difluorostyryl)-N,N-
dimethylaniline (compound 4r) had the best activity. The 
ortho- and meta-N,N-dimethylamino analogs of compound 
4r (i.e., compounds 4p and 4q) are not as active as compound 
4r, indicating that the para-dimethylamino in compound 4r is 
55 important for its activity (FIG. 6C). Based on the structure of 
compound 4r, two trihalogenated dimethylaminostilbenes 
were synthesized (compounds 4v and 4w) in which two of the 
fluorine substituents are in the 2'- and 6'-positions (FIG. 6D). 
Although compounds 4v and 4w were active at 10 f.LM, they 
60 showed no significant improvements over compound 4r. 
When the stilbene carbon-carbon double bond in compound 
4r was reduced to a saturated, single bond in the 1,2-diaryle-
thane compound 5r, the activity was lost, suggesting that the 
double bond is essential for biological activity (FIG. 6D). 
65 LS174 CRC cells were treated with different dosages of com-
pound 4r and it was found that compound 4r significantly 
inhibited Wnt target genes at 2.5 f.LM and was even active at 
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0.5 f.LM(FIG. 6E). For example, based on the Western blot and 
cell proliferation assays, it was determined that stilbene 4r 
was 10- to 100-fold more potent than resveratrol and pteros-
tilbene. 
42 
CRC cells (FIG. SC). RT-PCR assay suggested that com-
pound 4r strongly inhibited the transcription of Wnt target 
genes. It also inhibited TCF4 genes, but had no significant 
effects on pygopus2 genes, which suggests that these haloge-
Example 6 
5 nated stilbene analogs inhibit Wnt/mediated transcription at 
multiple levels (FIG. SD). 
Halogenated Stilbene Analogs Inhibit CRC In Vitro 
and In Vivo 
10 
In this example, the effects of the stilbene analogs of the 
present disclosure on CRC cells growth was analyzed. Con-
sistent with the Western blot results, stilbene compound 4r 
was more potent than compound 4e in the cell proliferation 
assay; it inhibited LS 174 cell proliferation at nanomolar 15 
concentrations (FIG. 7 A). To test the effects of compound 4r 
on tumor growth in vivo, LS174 cells were injected subcuta-
neously into the flanks of a thymic nude mice, which had been 
randomized into two groups. One group of mice was treated 
with compound 4r (20 mg/kg/day) dissolved in corn oil by 20 
intraperitoneal (ip) injection. The control mice were treated 
with the same volume of com oil (50 f.LL) by ip injection. The 
mice were weighted and tumors measured twice weekly. The 
compound 4rtreated mice and control mice had no significant 
difference in body weight within one month (FIGS. 7B and 25 
7C), suggesting that compound 4r has no significant toxic 
effect at this dosage. However, the growth of tumor 
xenografts were significantly inhibited by 4r treatment (FIG. 
7D). 
Therefore, as shown in this example, the halogenated stil- 30 
bene analogs of the present disclosure are capable of inhibit-
ing CRC both in vitro and in vivo. In another study, it was 
shown that mice could tolerate at least 200 mg/kg of a halo-
genated stilbene analog, FIDAS 4dd. The body weights in 
these mice were reduced after one week but were recovered to 35 
normal weight after stopping 4dd treatment (data not shown). 
Example 7 
Example 8 
Target Identification for Halogenated Stilbene 
Analogs 
Materials and Methods: 
The following materials and methods have been used to 
generate the results in this and other examples in the applica-
tion. 
Western Blot and Cell Proliferation Assay. 
The activity of fluorinated N,N-dialkylaminostilbenes (FI-
DAS or FIDAS agents) on Wnt signaling activity in cancer 
cells were analyzed by Western blot with antibodies against 
Wnt target genes, such as c-Myc, Axin2 The effects ofFIDAS 
agents on cancer cell growth were analyzed using Cell Viabil-
ity Analyzer (Beckman Coulter, Vi-Cell XR). These assays 
have been described previously (see Zhang eta!., J. ofMed. 
Chern. 54, 1288-1297 (2011)). 
Lentivirus-Mediated shRNA Assay. 
ShRNA constructs for MAT2A and MAT2B were ordered 
from Sigma. 293T cells were transfected with lentivirus pack-
aging plasmids psPAX2 and pMD2.G, as well as control or 
MAT2A/2B shRNA plasmids. Lentivirus stock was collected 
48 h after transfection. HT29, LS174T and Hep3B cell lines 
were infected by the lentivirus stock for 12 h, followed by 
sustained growth in fresh medium for 36-48 h. Infected cell 
lines were seeded in 12-well plate for proliferation assay. 
ShRNA efficiency was tested by western blot using lysate 
from 293T cells co-transfected with pcDNA3.1-MAT2A/2B 
and pLK0.1-shRNA plasmids. 
Protein Purification. 
To purifY the FIDAS target, LS174T celllysates were incu-
Halogenated Stilbene Analogs Inhibit Wnt Signaling 
in the Nucleus 
The stilbene analogs of the present disclosure and in par-
ticular, (E)-4-(2,6-difluorostyryl)-N,N -diethylaniline (com-
pound 4s) (FIG. 8) exhibit strong fluorescence at 365 nm 
(FIG. SA), albeit compound 4s is slightly less active than 
compound 4r (FIG. SB). Nevertheless, compound 4s lends 
itself well to a mechanistic study of the site of action of these 
compounds. LS174 cells were treated with 10 f.LM of com-
pound 4s for 2 h, 6 h, 12 h, and 24 h. The cells were fixed and 
analyzed by confocal fluorescence microscopy. It was found 
that compound 4s was localized throughout the nucleus and 
cytoplasm at 2 h. After 12 h, the nuclear levels of compound 
4s were decreased (data not shown, see Zhang eta!., J. of 
Med. Chern. 54, 1288-1297 (2011)). To study the effects of 
these compounds on ~-catenin localization, LS 17 4 cells were 
treated with 10 f.LM of compound 4r for 24 h. The cells were 
fixed and ~-catenin localization analyzed by immunofluores-
cence. The nuclear ~-catenin levels were decreased in com-
pound 4r treated cells compared with the DMSO-treated 
cells. However, significant levels of nuclear ~-catenin were 
still detected in the nucleus of compound 4r treated cells, 
suggesting that compound 4r may also inhibit Wnt signaling 
though mechanisms other than regulating ~-catenin level and 
localization. The downstream factors of ~-catenin were ana-
lyzed and it was found that the protein levels of TCF4 and 
pygopus2 were reduced by compound 4r and resveratrol in 
40 bated with streptavidin beads and biotinylatedFIDAS reagent 
13 (see FIGS. 4 and lOA) at 4° C. overnight. The beads were 
washed 3 times with cell lysis buffer. Binding proteins were 
elution with 2.5 mM D-Biotin. The purified samples were 
separated by 4-12% gradient SDS-PAGE and analyzed by 
45 silver staining or Sypro Ruby fluorescent staining. The pro-
tein bands specifically presented in the samples of the bioti-
nylated analog were excised and analyzed by LC-MS/MS as 
previously described (See Zhang et a!., Novel cross talk of 
Kruppel-like factor 4 and beta-catenin regulates normal intes-
50 tina! homeostasis and tumor repression. Mol Cell Biol 2006, 
26, 2055-64). 
MAT2A and MAT2B were Cloned into pGEX6p3 Vector. 
The constructs were transfected into E. coli BL21. The 
GST-fusion proteins were induced by IPTG and purified by 
55 glutathione beads as described previously (See Liu, beta-Trcp 
couples beta-catenin phosphorylation-degradation and regu-
lates Xenopus axis formation. Proc Nat! A cad Sci USA 1999, 
96, 6273-8). For the binding assay, purified proteins were 
incubated with streptavidin beads and biotinylated FIDAS 13 
60 described above. Eluted proteins were analyzed by western 
blot with antibodies against GST, MAT2A or MAT2B. 
SAM and SAHAnalysis by LC-MS/MS. 
The LC-MS/MS system consisted of two Varian ProS tar 
210 LC Pumps coupled with a Varian 1200L triple quadru-
65 pole mass spectrometer. The separation was performed on a 
Hypercarb colunm (50 mmx2.1 mm, 3 mm, Thermo Scien-
tific #35003-052130). Gradient elution started with 98% 
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solution A (0.1% formic acid in water), followed by an 
increase to 38% solution B (0.1% formic acid in acetonitrile) 
44 
Example 9 
The Effects ofHalogenated Stilbene Analogs on 
MAT2A Enzyme Activity 
Methionine adenosyltransferases catalyze the reaction of 
S-adenoslmethionine (SAM or AdoMet) synthesis fromATP 
and L-methionine. In mannnals, there are three types of 
methionine adenosyltransferases, MATIIIII and MATH. 
MATI and III are tetramer or dimer of a! subunit (encoded by 
MAT1A) and are expressed in adult liver. MAT2A encodes 
the catalytic subunit (a2) of type II methionine adenosyl-
transferases. MAT2B encodes the regulating subunit of a2. 
MAT2A and MAT2B are widely expressed in proliferating 
cells and cancers. MAT2A controls the cellular levels of 
in 8 min. The colunm was than flushed with 90% B for 5 min 
and regenerated with 98% A for another 8 min. The flow rate 
was 0.25 mL/min Between the 3rd and 11th min, the eluent 5 
was switched to the ion source of the mass spectrometer. The 
precursor product transitions for SAM (m/z 399~ 250), SAH 
(m/z 385~250) and [d-4]-SAH (m/z 389~436) were moni-
tored. The optimized ion source parameters were: Capillary 
Voltage: 32 V for both SAM and SAH, Collision energy: 9 V 10 
and 7V for SAM and SAH, respectively, Needle voltage: 
5000 V and the Shield voltage: 600V. Nitrogen was used as 
the drying gas at a temperature of 300° C. and the interface 
heater was set to 50° C. The drying gas and nebulizing gas 
were set to 20 and 50 psi, respectively. 15 SAM, which is the major methyl donor for many cellular 
methylation reactions, including DNA methylation and pro-
tein methylation. 
Cell Based SAM Analysis. 
LS174T cells were cultured in RPMI1640 medium con-
taining 5% FBS. Cells were treated with FIDAS reagents for 
24 h or 48 hours. Cells were harvested and weighted. Per-
chloric acid (0.4M) was added to cell pellet (1 00 fll/1 0 mg) for 20 
deproteinization. The sample was mixed vigorously and cen-
trifuged at 10,000 g. 60 fll supernatant was mixed with 20 fll 
internal standard (5 flg/ml of SAH-d4). Sample was adjusted 
to pH 5-7 with 2.5 M K2 HP04 and kept on ice for 15 min to 
precipitate potassium perchlorate. Samples were centrifuged 25 
twice at 10000 g for 15 min. 5 ul of supernatants were ana-
lyzed by LC-MS/MS using a modified method based on a 
previous publication (see Krijt eta!., J Chromatogr B Analyt 
TechnolBiomedLifeSci 877,2061-6, (2009)). SAMandSAH 
standard were prepared by serial dilutions with 0.4 M per- 30 
chloric acid (PCA), the individual calibration points were 
0.05, 0.5, 5, 50 f.tg/ml. 
SAM Synthesis. 
5 mg purified MAT2A was incubated with 1 mM L-me-
thionine and 1 mMATP in 500 ml reaction solution (50 mM 35 
Tris.Cl, 50 mM KCI, 10 mM MgCI2) for 5 min at 25° C. The 
reaction was stopped with 500 ml 0.4 M Perchloric acid and 
neutralized with 2.5 M K2HP04. The samples were kept on 
ice for 15 min to precipitate potassium perchlorate as 
described above. SAM was analyzed by LC-MS/MS. 40 
In this example, by using the biotinylated compounds of 
the present disclosure, it was possible to purify and identify 
methionine adenosyltransferase 2A (MAT2A) as the direct 
target for the halogenated stilbene analogs described herein. 
To test ifFIDAS reagents inhibit the enzymatic activity of 
MAT2A, an LC-MS/MS method was developed to detect and 
analyze AdoMet (SAM) and SAH (S-adenosylhomocys-
teine) (data not shown). Furthermore, an in-vitro method was 
developed to synthesize SAM from L-methionine and ATP. 
The results show that both resveratrol and compound 4r 
inhibit MAT2A activity in SAM synthesis, and that 10 f.LM of 
compound 4r reduces MAT2A activity in LS174 cells more 
significantly than 30 f.LM of resveratrol. These data suggest 
that 4 r is significantly more potent than resveratrol in MAT2A 
inhibition (FIG. llA). A test of another halogenated stilbene 
analog in an assay for inhibition of SAM and SAH showed 
that compound 4dd was even more potent than 4r in inhibition 
ofMAT2A and reduction of SAM and SAH (FIGS. llB and 
llC). In FIGS. llB and llC, the effects of3 f.LM of 4dd was 
compared with the 10 uM of 4 r and 30 uM of resveratrol in 
causing reduction in SAM and SAH concentrations, respec-
tively. These results show that compound 4dd is even more 
potent than compound 4r which is significantly more potent 
than resveratrol. 
Example 10 
The Effects of MAT2A and MAT2B Genes 
Inhibition on Cell Proliferation 
In this example, the effects of inhibition of MAT2A and 
MAT2B genes on cell proliferation were studied. To study the 
biological function ofMAT2A and MAT2B in cell prolifera-
tion, the expression of MAT2A or MAT2B genes were 
knocked down by shRNAs (FIGS. 12A and 12B). Both 
MAT2A and MAT2B shRNAs inhibited proliferation ofliver 
cancer cells Hep3B (FIG. 12C). To test if MAT2A and 
MAT2B are required for colon cancer cell proliferation, 
MAT2A and MAT2B genes were knocked down in colon 
cancer cells, LS174T and HT29. In a time-course study for 
the effects of MAT2A and MAT2B inhibition on cell prolif-
CRC cell lysates were incubated with streptavidin 45 
beads±biotin-FIDAS (FIG. 9A) and binding proteins were 
elution with 2.5 mM D-Biotin. The purified samples were 
separated by 4-12% gradient SDS-PAGE and analyzed by 
silver staining (FIG. 9B). Two specific protein bands were 
identified. These bands were analyzed by MALDI-TOF/TOF so 
and LC-MS/MS mass spectrometry methods. These two 
bands were identified to be methionine adenosyltransferase 
2A (MAT2A), the upper band, and methionine adenosyltrans-
ferase 2B (MAT2B), the lower band, by both methods (FIG. 
9B). 
Since MAT2A and MAT2B bind each other and form a 
complex, to determine which subunit directly interacts with 
FIDAS reagents, recombinant MAT2A and MAT2B were 
purified and tested for interaction with FIDAS. Briefly, GST-
MAT2A and GST-MAT2B fusion proteins were expressed 60 
and purified from E. coli. These proteins were incubated with 
streptavidin beads with or without biotinylated derivative 13 
(FIG. 9A). The binding proteins were eluted by 2.5 mM 
D-biotin and analyzed by Western blot with an anti-GST-Ab. 
55 eration in LS174T and HT29, it was determined that both 
MAT2A and MAT2B shRNAs inhibit proliferation of colon 
cancer cells, and that inhibition ofMAT2A is more effective 
in inhibition of cancer cell proliferation than inhibition of 
MAT2B (FIGS. 13A and 13B). 
It was found MAT2A directly binds to biotinylated FIDAS 65 
reagents; MAT2B binds FIDAS reagents indirectly through 
MAT2A (FIG. 10). 
Example 11 
The Effects the Metabolites of the Halogenated 
Stilbene Analogs on Cell Proliferation In-Vitro 
As previously shown, several metabolites of the haloge-
nated stilbenes of the present disclosure were synthesized 
US 9,132,102 B2 
45 
(Example 2 and FIG. 3). In this study, the effects of some of 
these metabolites on cell proliferation were studied. Com-
pounds 4aa, 4dd and 4ee were significantly more effective 
than resveratrol, as well as compound 4r (FIGS. 14 and 15). 
Example 12 
The Effects the Metabolites of the Halogenated 
Stilbene Analogs on Cell Proliferation In-Vivo in 
Mice 
In this study, the oral efficacy of the metabolites of halo-
genated stilbene analogs were tested in mice. 
Xenografted nude mice were developed according to the 
protocol described above and in Zhang et a!., J. of Med. 
Chern. 54, 1288-1297 (2011)). Briefly, HT29 cells were 
injected subcutaneously into the flanks of nude mice. The 
mice were then treated with 20 mg/kg compound 4dd dis-
solved in PEG400 by gavage. As described in Example 7, an 
IP injection of compound 4r dissolved in corn oil inhibited 
xenograft tumor growth. Here, it was also shown that the 
halogenated stilbenes of the present disclosure can also be 
dissolved in other solvents such as PEG400 and cycledextran. 
46 
Example 14 
Binding Studies of MAT2A and Halogenated 
Stilbene Analogs 
To test if the halogenated stilbene analogs of the present 
disclosure also bind MATlA, a His-tagged MATlA was 
cloned in and purified from E. coli. An in vitro binding assay 
was performed, and the results show that the compounds 
10 tested only bound to MAT2A but not MATlA (FIG. 18B). 
According to published MAT structures, several key residues 
are involved in substrate binding and catalysis. Among these 
key residues, lysine 265 is conserved between MAT1A and 
MAT2A and among different species. When lysine 265 was 
15 mutated to leucine (K265L, FIG. 18A), the binding between 
MAT2A and compound 13 was significantly decreased, sug-
gesting that K265 is involved in binding with compounds of 
the present disclosure (FIG. 18C). Taken together, the FIDAS 
reagents are specific inhibitors ofMAT2A, and are promising 
20 drug candidates for multiple cancers as well as metabolic 
diseases. 
Example 15 
The results show that 4dd significantly inhibits the growth 25 
of xenografted tumors without any adverse effect on body 
weight (FIG. 16). 
The Efficacy ofthe Halogenated Stilbene Analogs in 
Inhibiting Other MAT2A-Related Diseases or 
Disorders 
Example 13 
Halogenated Stilbene Analogs Inhibit Other Cancer 
Types 
As discussed above, the halogenated stilbene analogs of 
the present disclosure bind to MAT2A and inhibit the enzyme 
function which leads to inhibition of colon cancer cell prolif-
eration. Since, for example, in liver cancer, it has been shown 
that the expression ofMAT1A is decreased while the expres-
sion ofMAT2A is increased (see Cai eta!., Hepatology 24, 
1090-7 (1996) ), Applicants hypothesized that the compound 
of the disclosure should inhibit proliferation of other types of 
cancers, particularly those in which the MAT2A activity or 
expression is increased. 
To test this hypothesis, a number cancer cell lines were 
treated with the halogenated stilbene analogs of the present 
disclosure. The results show that the halogenated stilbene 
analogs are capable of inhibiting other cancer types as well. 
As showninFIG.17, the compounds of the present disclosure 
inhibited cell proliferation ofbreast cancer (FIG. 17A), lung 
cancer (FIGS. 17B and C), carcinoid tumor (FIG. 17D) and 
prostate cancer (FIG. 17E) cell lines. 
<160> NUMBER OF SEQ ID NOS, 18 
<210> SEQ ID NO 1 
<211> LENGTH, 18 
<212> TYPE, PRT 
SEQUENCE LISTING 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, B-Actin primer 
<400> SEQUENCE, 1 
It has also been shown that MAT2A is induced by hepatitis 
30 B infection in the liver Liuetal.,J. Biol. Chern. 286, 17168-80 
(2011)). Since the compounds of the present disclosure are 
effective in inhibiting MAT2A and reducing SAM, these 
compounds must be effective in treating any disease or con-
dition in which MAT2A may be involved, including, but not 
35 limited to, metabolic disorders such as diabetes, heart disease, 
aging, obesity, and neurodegenerative disease, such as Alzhe-
imer's and Parkinson diseases 
Only the preferred embodiment of the present disclosure 
and examples of its versatility are shown and described in the 
40 present disclosure. It is to be understood that the present 
disclosure is capable of use in various other combinations and 
environments and is capable of changes or modifications 
within the scope of the inventive concept as expressed herein. 
Thus, for example, those skilled in the art will recognize, or be 
45 able to ascertain, using no more than routine experimentation, 
numerous equivalents to the specific substances, procedures 
and arrangements described herein. Such equivalents are con-
sidered to be within the scope of this disclosure, and are 
covered by the following claims. Any or all patents and/or 
publications including journal articles cited in this disclosure 
are expressly incorporated herein by reference. 
Cys Ala Ala Cys Cys Gly Cys Gly Ala Gly Ala Ala Gly Ala Thr Gly 
1 5 10 15 
Ala Cys 
<210> SEQ ID NO 2 
<211> LENGTH, 18 
<212> TYPE, PRT 
47 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, B-actin primer 
<400> SEQUENCE, 2 
US 9,132,102 B2 
-continued 
Ala Gly Gly Ala Ala Gly Gly Cys Thr Gly Gly Ala Ala Gly Ala Gly 
1 5 10 15 
Thr Gly 
<210> SEQ ID NO 3 
<211> LENGTH, 22 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, survivin primer 
<400> SEQUENCE, 3 
Cys Ala Thr Thr Cys Gly Thr Cys Cys Gly Gly Thr Thr Gly Cys Gly 
1 5 10 15 
Cys Thr Thr Thr Cys Cys 
20 
<210> SEQ ID NO 4 
<211> LENGTH, 22 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, survivin primer 
<400> SEQUENCE, 4 
Gly Cys Gly Cys Ala Cys Thr Thr Thr Cys Thr Cys Cys Gly Cys Ala 
1 5 10 15 
Gly Thr Thr Thr Cys Cys 
20 
<210> SEQ ID NO 5 
<211> LENGTH, 19 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, c-Myc primer 
<400> SEQUENCE, 5 
Thr Gly Gly Gly Cys Thr Gly Thr Gly Ala Gly Gly Ala Gly Gly Thr 
1 5 10 15 
Thr Thr Gly 
<210> SEQ ID NO 6 
<211> LENGTH, 19 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, c-Myc primer 
<400> SEQUENCE, 
Thr Ala Thr Gly Thr Gly Gly Ala Gly Cys Gly Gly Cys Thr Thr Cys 
1 5 10 15 
Thr Cys Gly 
48 
US 9,132,102 B2 
49 50 
-continued 
<210> SEQ ID NO 7 
<211> LENGTH, 20 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, axin2 primer 
<400> SEQUENCE, 7 
Cys Ala Cys Cys Ala Cys Cys Ala Cys Cys Ala Cys Cys Ala Cys Cys 
1 5 10 15 
Ala Thr Thr Cys 
20 
<210> SEQ ID NO 8 
<211> LENGTH, 20 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, axin2 primer 
<400> SEQUENCE, 8 
Gly Cys Ala Thr Cys Cys Ala Cys Thr Gly Cys Cys Ala Gly Ala Cys 
1 5 10 15 
Ala Thr Cys Cys 
20 
<210> SEQ ID NO 9 
<211> LENGTH, 20 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, TCF4 primer 
<400> SEQUENCE, 9 
Cys Ala Cys Cys Ala Cys Ala Thr Cys Ala Thr Ala Cys Gly Cys Thr 
1 5 10 15 
Ala Cys Ala Cys 
20 
<210> SEQ ID NO 10 
<211> LENGTH, 20 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, TCF4 primer 
<400> SEQUENCE, 10 
Cys Gly Ala Cys Cys Thr Thr Thr Gly Cys Thr Cys Thr Cys Ala Thr 
1 5 10 15 
Thr Thr Cys Cys 
20 
<210> SEQ ID NO 11 
<211> LENGTH, 19 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, pygopus2 primer 
<400> SEQUENCE, 11 
Gly Gly Cys Cys Gly Gly Thr Cys Thr Gly Cys Ala Ala Ala Thr Gly 
1 5 10 15 
Ala Ala Gly 
US 9,132,102 B2 
51 52 
-continued 
<210> SEQ ID NO 12 
<211> LENGTH, 19 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, pygopus2 primer 
<400> SEQUENCE, 12 
Thr Cys Cys Ala Cys Cys Thr Cys Cys Ala Gly Thr Gly Cys Thr Gly 
1 5 10 15 
Thr Ala Gly 
<210> SEQ ID NO 13 
<211> LENGTH, 22 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Lgr5 primer 
<400> SEQUENCE, 13 
Cys Cys Thr Gly Cys Thr Thr Gly Ala Cys Thr Thr Thr Gly Ala Gly 
1 5 10 15 
Gly Ala Ala Gly Ala Cys 
20 
<210> SEQ ID NO 14 
<211> LENGTH, 20 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Lgr5 primer 
<400> SEQUENCE, 14 
Ala Thr Gly Thr Thr Cys Ala Cys Thr Gly Cys Thr Gly Cys Gly Ala 
1 5 10 15 
Thr Gly Ala Cys 
20 
<210> SEQ ID NO 15 
<211> LENGTH, 20 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, CD44 primer 
<400> SEQUENCE, 15 
Cys Ala Gly Ala Ala Thr Gly Gly Cys Thr Gly Ala Thr Cys Ala Thr 
1 5 10 15 
Cys Thr Thr Gly 
20 
<210> SEQ ID NO 16 
<211> LENGTH, 20 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, CD44 primer 
<400> SEQUENCE, 16 
Cys Ala Ala Ala Thr Gly Cys Ala Cys Cys Ala Thr Thr Thr Cys Cys 
1 5 10 15 
Thr Gly Ala Gly 
20 
US 9,132,102 B2 
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-continued 
<210> SEQ ID NO 17 
<211> LENGTH, 20 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Ki67 primer 
<400> SEQUENCE, 17 
Ala Cys Ala Gly Ala Gly Thr Gly Cys Thr Cys Ala Ala Cys Ala Ala 
1 5 10 15 
Cys Thr Thr Cys 
20 
<210> SEQ ID NO 18 
<211> LENGTH, 20 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Ki67 primer 
<400> SEQUENCE, 18 
Gly Cys Thr Thr Gly Cys Ala Gly Ala Gly Cys Ala Thr Thr Thr Ala 
1 5 10 15 
Thr Cys Ala Gly 
20 
What is claimed is: 30 2. The method according to claim 1, whereinAr2 is pyridyl 
substituted with alkylamino, or dialkylamino. 
3. The method according to claim 1, wherein X is one, two 
or three fluorine and/ or chlorine on Ar 1 . 
1. A method of treating liver cancer or colon cancer, the 
method comprising administering to a patient in need of such 
treatment an effective amount of a compound according to 
formula (I): 4. The method according to claim 1, wherein X represents 
35 at least one fluorine and at least one chlorine on Ar 1 . 
(I) 
or a pharmaceutically acceptable salt thereof, wherein Ra 
and R6 are independently H, alkyl, halo, alkoxy, cyano; 
X represents at least one halogen onAr1 ; Ar1 is phenyl 
andAr2 is pyridyl; provided thatAr2 contains at least one 
40 
NRcRdz substituent onAr2 where Rc isH, alkyl, alkoxy, 
aryl, heteroaryl, Rd is an unsubstituted alkyl group, Z is 
an unshared pair of electrons, H, alkyl, oxygen. 
5. The method according to claim 1, wherein, X is one or 
more fluorine and/or chlorine. 
6. The method according to claim 1, wherein Rc is H or a 
lower alkyl and Rd is a lower unsubstituted alkyl. 
7. The method according to claim 1, wherein X is one or 
more fluorine and/or chlorine and Rc isH or a lower alkyl and 
R dis a lower unsubstituted alkyl. 
* * * * * 
